Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Lung Neoplasms ALK gene crizotinib
Brief summary
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Interventions
DRUGPF-02341066
PF-02341066, 250 mg BID will be administered orally on a continuous schedule
DRUGPemetrexed
Pemetrexed, 500 mg/m\^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
DRUGDocetaxel
Docetaxel, 75 mg/m\^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
Sponsors
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* histologically or cytologically proven diagnosis of non-small cell lung cancer * positive for the ALK fusion gene (test provided by a central laboratory) * must have had disease progression after only one prior chemotherapy and that regimen but must have included one platinum drug * tumors must be measurable
Exclusion criteria
* prior treatment with PF-02341066 * current treatment in another clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) | PFS: Time in months from randomization to first documentation of objective disease progression as determined by independent radiology review or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of randomization plus 1) divided by 30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria version 1.1 (RECIST v1.1), as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival Probability at Months 6 and 12 | Month 6, 12 | Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method. |
| Percentage of Participants With Objective Response (OR) | Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) | Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 millimeter \[mm\] short axis). PR: at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. Objective response is based on independent radiology review. |
| Percentage of Participants With Disease Control at Week 6 | Week 6 | Disease control: participants with CR, PR, or stable disease (SD) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Disease control is based on independent radiology review. |
| Percentage of Participants With Disease Control at Week 12 | Week 12 | Disease control: participants with CR, PR, or SD according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. |
| Duration of Response (DR) | Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) | Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.02. DR was calculated for the subgroup of participants with a confirmed objective tumor response. |
| Time to Tumor Response (TTR) | Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks) | Time from date of randomization to first documentation of objective tumor response. TTR was calculated for the subgroup of participants with objective tumor response. Objective tumor response was defined as CR or PR according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. |
| Overall Survival (OS) | Randomization until death (up to 4.5 years) | OS: Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. |
| Number of Participants With Categorical Maximum QTcF for Crizotinib | Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 1, 2 | QT interval corrected using Fridericia's formula (QTcF): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\<) 450 milliseconds (msec), 450 msec to \<480 msec, 480 msec to \<500 msec, and more than or equal to (\>=) 500 msec. A participant is reported only once under the maximum QTcF interval observed at any of the time-points. Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis. |
| Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins | Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 2, end of treatment (up to 112 weeks) | Descriptive statistics (absolute value and change from baseline as measured by ratio to baseline) for each best overall response category (CR, PR, SD, PD or combined) have been used to summarize the data from optional soluble c-Met ectodomain assays for crizotinib treated patients. |
| Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough | Baseline up to end of treatment (up to 112 weeks) | TTD in pain (pain in chest from European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer \[EORTC QLQ-LC13\]), dyspnea (from EORTC QLQ-LC13), or cough (from EORTC QLQ-LC13) symptoms was defined as the time from randomization to the earliest time the participant's score showed a 10 point or higher increase from baseline in any of the three symptoms from the instrument. The transformed score of pain, dyspnea, and cough symptom scales of EORTC QLQ-LC13 range from 0 to 100, greater scores = higher symptom severity. |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Baseline, Day (D) 1 of each cycle (C) until disease progression, end of treatment (EOT, up to 112 weeks) | EORTC QLQ-C30: included global health status/quality of life (QoL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score for Global Qol/functional scales=better level of QoL/functioning or higher score for symptom scale=greater degree of symptoms. |
| European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks) | QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: 1 'Not at All' to 4 'Very Much'. Scores averaged, transformed to 0-100 scale; higher symptom score = greater degree of symptoms. |
| European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks) | EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state. |
| Plasma Concentration of Crizotinib | Pre-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 3, 5 | Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis. |
Countries
Australia, Brazil, Bulgaria, Canada, China, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, Sweden, Taiwan, United Kingdom, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Crizotinib Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred. | 173 |
| Chemotherapy Pemetrexed 500 mg/m\^2 intravenous infusion over 10 minutes or docetaxel 75 mg/m\^2 intravenous infusion over 1 hour on Day 1 of 21-day cycle, as per investigator discretion. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred. | 174 |
| Total | 347 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Death | 115 | 24 |
| Overall Study | Lost to Follow-up | 8 | 0 |
| Overall Study | Other | 5 | 144 |
| Overall Study | Withdrawal by Subject | 5 | 2 |
Baseline characteristics
| Characteristic | Crizotinib | Chemotherapy | Total |
|---|---|---|---|
| Age, Continuous | 50.3 years STANDARD_DEVIATION 13.1 | 49.8 years STANDARD_DEVIATION 13 | 50.0 years STANDARD_DEVIATION 13 |
| Gender Female | 98 Participants | 95 Participants | 193 Participants |
| Gender Male | 75 Participants | 79 Participants | 154 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 172 / 172 | 169 / 171 |
| serious Total, serious adverse events | 80 / 172 | 42 / 171 |
Outcome results
Primary
Progression-Free Survival (PFS)
PFS: Time in months from randomization to first documentation of objective disease progression as determined by independent radiology review or to death due to any cause, whichever occurred first. PFS was calculated as (first event date minus the date of randomization plus 1) divided by 30.4. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria version 1.1 (RECIST v1.1), as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: Randomization until progressive disease (PD) or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)
Population: Full analysis set (FAS) included all participants who were randomized to study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib | Progression-Free Survival (PFS) | 7.7 months |
| Chemotherapy | Progression-Free Survival (PFS) | 3.0 months |
Comparison: P-value was obtained from 1-sided log-rank test stratified by Eastern Cooperative Oncology Group performance status (ECOG PS) score, brain metastases, and prior epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment. The hazard ratio and corresponding 95% confidence interval (CI) from the stratified Cox Proportional Hazards model were also presented.p-value: <0.000195% CI: [0.371, 0.638]Log Rank
Secondary
Duration of Response (DR)
Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.02. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)
Population: FAS included all participants who were randomized to study treatment. Here 'N' (number of participant analyzed) signifies participants with objective tumor response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib | Duration of Response (DR) | 32.1 weeks |
| Chemotherapy | Duration of Response (DR) | 24.4 weeks |
Secondary
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30: included global health status/quality of life (QoL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score for Global Qol/functional scales=better level of QoL/functioning or higher score for symptom scale=greater degree of symptoms.
Time frame: Baseline, Day (D) 1 of each cycle (C) until disease progression, end of treatment (EOT, up to 112 weeks)
Population: FAS included all participants who were randomized to study treatment. Here N (number of participants analyzed) signifies participants who were evaluable for this measure and n signifies participants who were evaluable for specified time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C24D1 (n=20, 3) | 85.8 units on a scale | Standard Deviation 19.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C30D1 (n=8, 1) | 4.2 units on a scale | Standard Deviation 7.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C25D1 (n=18, 3) | 89.8 units on a scale | Standard Deviation 19.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C31D1 (n=7, 0) | 4.8 units on a scale | Standard Deviation 8.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C21D1 (n=30, 8) | 84.5 units on a scale | Standard Deviation 17.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C32D1 (n=6, 0) | 5.6 units on a scale | Standard Deviation 8.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C26D1 (n=14, 3) | 78.6 units on a scale | Standard Deviation 28.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C33D1 (n=6, 0) | 2.8 units on a scale | Standard Deviation 6.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C25D1 (n=18, 3) | 86.1 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C34D1 (n=5, 0) | 3.3 units on a scale | Standard Deviation 7.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C27D1 (n=14, 2) | 85.7 units on a scale | Standard Deviation 15.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C35D1 (n=4, 0) | 8.3 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C31D1 (n=7, 0) | 76.2 units on a scale | Standard Deviation 28.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C28D1 (n=11, 2) | 83.3 units on a scale | Standard Deviation 26.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C26D1 (n=14, 3) | 81.0 units on a scale | Standard Deviation 26 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: Baseline (n=165, 163) | 31.1 units on a scale | Standard Deviation 28.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C29D1 (n=8, 2) | 83.3 units on a scale | Standard Deviation 25.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C7D1 (n=115, 52) | 17.4 units on a scale | Standard Deviation 20.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C14D1 (n=66, 19) | 84.5 units on a scale | Standard Deviation 19.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C8D1 (n=111, 43) | 15.8 units on a scale | Standard Deviation 19.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C30D1 (n=8, 1) | 85.4 units on a scale | Standard Deviation 24.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C9D1 (n=101, 37) | 13.9 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C27D1 (n=14, 2) | 76.2 units on a scale | Standard Deviation 25.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C10D1 (n=94, 33) | 17.7 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C31D1 (n=7, 0) | 73.8 units on a scale | Standard Deviation 38.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C19D1 (n=40, 9) | 14.2 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C32D1 (n=6, 0) | 87.5 units on a scale | Standard Deviation 17.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C20D1 (n=35, 8) | 10.5 units on a scale | Standard Deviation 17.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C32D1 (n=6, 0) | 83.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C21D1 (n=30, 8) | 13.3 units on a scale | Standard Deviation 16.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C28D1 (n=11, 2) | 78.8 units on a scale | Standard Deviation 21.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C22D1 (n=24, 7) | 13.9 units on a scale | Standard Deviation 19.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C33D1 (n=6, 0) | 94.4 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C23D1 (n=23, 4) | 9.4 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C22D1 (n=24, 7) | 83.7 units on a scale | Standard Deviation 21.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C24D1 (n=20, 3) | 18.3 units on a scale | Standard Deviation 20.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C34D1 (n=5, 0) | 96.7 units on a scale | Standard Deviation 7.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C25D1 (n=18, 3) | 11.1 units on a scale | Standard Deviation 16.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C29D1 (n=8, 2) | 87.5 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C26D1 (n=14, 3) | 14.3 units on a scale | Standard Deviation 28.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C35D1 (n=4, 0) | 91.7 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C27D1 (n=14, 2) | 11.9 units on a scale | Standard Deviation 16.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C33D1 (n=6, 0) | 90.3 units on a scale | Standard Deviation 13.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C28D1 (n=11, 2) | 12.1 units on a scale | Standard Deviation 16.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C36D1 (n=1, 0) | 66.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C29D1 (n=8, 2) | 4.2 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C30D1 (n=8, 1) | 83.3 units on a scale | Standard Deviation 23.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C30D1 (n=8, 1) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C37D1 (n=1, 0) | 66.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C18D1 (n=45, 11) | 12.6 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C17D1 (n=47, 11) | 85.6 units on a scale | Standard Deviation 22 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C19D1 (n=40, 9) | 13.3 units on a scale | Standard Deviation 19.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: Baseline (n=165, 163) | 38.3 units on a scale | Standard Deviation 24.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C20D1 (n=35, 8) | 15.2 units on a scale | Standard Deviation 20.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C31D1 (n=7, 0) | 81.0 units on a scale | Standard Deviation 20.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C21D1 (n=30, 8) | 12.2 units on a scale | Standard Deviation 18.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C2D1 (n=155, 133) | 31.4 units on a scale | Standard Deviation 23.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C22D1 (n=24, 7) | 12.5 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C34D1 (n=5, 0) | 91.7 units on a scale | Standard Deviation 14.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C23D1 (n=23, 4) | 17.4 units on a scale | Standard Deviation 26.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C3D1 (n=154, 106) | 30.8 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C24D1 (n=20, 3) | 11.7 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C32D1 (n=6, 0) | 83.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C25D1 (n=18, 3) | 20.4 units on a scale | Standard Deviation 30.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C4D1 (n=135, 91) | 27.1 units on a scale | Standard Deviation 22.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C26D1 (n=14, 3) | 21.4 units on a scale | Standard Deviation 33.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C23D1 (n=23, 4) | 84.1 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C27D1 (n=14, 2) | 16.7 units on a scale | Standard Deviation 21.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C5D1 (n=123, 74) | 24.7 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C28D1 (n=11, 2) | 9.1 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C33D1 (n=6, 0) | 86.1 units on a scale | Standard Deviation 16.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C29D1 (n=8, 2) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C6D1 (n=120, 70) | 24.6 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C30D1 (n=8, 1) | 12.5 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C35D1 (n=4, 0) | 83.3 units on a scale | Standard Deviation 20.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C7D1 (n=115, 52) | 23.9 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C8/D1(n=111, 43) | 12.8 units on a scale | Standard Deviation 20.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C34D1 (n=5, 0) | 90.0 units on a scale | Standard Deviation 9.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C9/D1(n=101, 37) | 12.2 units on a scale | Standard Deviation 239 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C8D1 (n=111, 43) | 23.2 units on a scale | Standard Deviation 18.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C10/D1(n=94, 33) | 12.4 units on a scale | Standard Deviation 22.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C13D1 (n=74, 21) | 84.9 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C11/D1(n=84, 25) | 13.5 units on a scale | Standard Deviation 19.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C9D1 (n=101, 37) | 22.9 units on a scale | Standard Deviation 21.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C12/D1(n=76, 23) | 11.0 units on a scale | Standard Deviation 21.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C35D1 (n=4, 0) | 95.8 units on a scale | Standard Deviation 8.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C13/D1(n=74, 21) | 9.5 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C10D1 (n=94, 33) | 21.4 units on a scale | Standard Deviation 20 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C15/D1(n=62, 16) | 8.6 units on a scale | Standard Deviation 20.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C36D1 (n=1, 0) | 58.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C16/D1(n=53, 12) | 8.8 units on a scale | Standard Deviation 18.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C11D1 (n=84, 25) | 22.1 units on a scale | Standard Deviation 19.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C17/D1(n=47, 11) | 8.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C36D1 (n=1, 0) | 100.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C18/D1(n=45, 11) | 11.1 units on a scale | Standard Deviation 17.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C12D1 (n=76, 23) | 21.9 units on a scale | Standard Deviation 22.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C19/D1(n=40, 9) | 8.3 units on a scale | Standard Deviation 16.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C24D1 (n=20, 3) | 87.9 units on a scale | Standard Deviation 16.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C20/D1(n=35, 8) | 7.6 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C13D1 (n=74, 21) | 23.3 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C21/D1(n=30, 8) | 11.1 units on a scale | Standard Deviation 16 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C37D1 (n=1, 0) | 83.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C22/D1(n=24, 7) | 6.9 units on a scale | Standard Deviation 13.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C14D1 (n=66, 19) | 21.7 units on a scale | Standard Deviation 21.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C19D1 (n=40, 9) | 25.0 units on a scale | Standard Deviation 25.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C37D1 (n=1, 0) | 58.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C20D1 (n=35, 8) | 22.9 units on a scale | Standard Deviation 26.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C15D1 (n=62, 16) | 20.8 units on a scale | Standard Deviation 22.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C21D1 (n=30, 8) | 24.4 units on a scale | Standard Deviation 28.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: Baseline (n=165, 162) | 68.0 units on a scale | Standard Deviation 27.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C22D1 (n=24, 7) | 18.1 units on a scale | Standard Deviation 24 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C18D1 (n=44, 11) | 86.4 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C23D1 (n=23, 4) | 11.6 units on a scale | Standard Deviation 19.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C6D1 (n=120, 70) | 10.1 units on a scale | Standard Deviation 15.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C24D1 (n=20, 3) | 21.7 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C2D1 (n=155, 133) | 75.9 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C25D1 (n=18, 3) | 22.2 units on a scale | Standard Deviation 32.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C16D1 (n=53, 12) | 22.2 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C26D1 (n=14, 3) | 26.2 units on a scale | Standard Deviation 32.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: Baseline (n=165, 162) | 85.6 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C27D1 (n=14, 2) | 35.7 units on a scale | Standard Deviation 40.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C17D1 (n=47, 11) | 23.4 units on a scale | Standard Deviation 20 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C28D1 (n=11, 2) | 21.2 units on a scale | Standard Deviation 16.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C30D1 (n=8, 1) | 26.4 units on a scale | Standard Deviation 24.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C29D1 (n=8, 2) | 29.2 units on a scale | Standard Deviation 21.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C3D1 (n=154, 106) | 78.5 units on a scale | Standard Deviation 24 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C30D1 (n=8, 1) | 29.2 units on a scale | Standard Deviation 27.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C31D1 (n=7, 0) | 28.6 units on a scale | Standard Deviation 16.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C31D1 (n=7, 0) | 33.3 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C25D1 (n=18, 3) | 81.5 units on a scale | Standard Deviation 19.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C32D1 (n=6, 0) | 33.3 units on a scale | Standard Deviation 42.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C32D1 (n=6, 0) | 25.9 units on a scale | Standard Deviation 5.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C33D1 (n=6, 0) | 38.9 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C4D1 (n=135, 90) | 79.4 units on a scale | Standard Deviation 23.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C34D1 (n=5, 0) | 40.0 units on a scale | Standard Deviation 43.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C33D1 (n=6, 0) | 18.5 units on a scale | Standard Deviation 11.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C35D1 (n=4, 0) | 33.3 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C2D1 (n=155, 133) | 85.5 units on a scale | Standard Deviation 18.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C34D1 (n=5, 0) | 15.6 units on a scale | Standard Deviation 16.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C5D1 (n=123, 74) | 79.4 units on a scale | Standard Deviation 23.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: EOT (n=49, 90) | 28.6 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C35D1 (n=4, 0) | 27.8 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: Baseline (n=165, 162) | 9.7 units on a scale | Standard Deviation 19.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C15D1 (n=62, 16) | 86.3 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C2D1 (n=155, 132) | 18.1 units on a scale | Standard Deviation 26.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C36D1 (n=1, 0) | 33.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C3D1 (n=153, 106) | 21.6 units on a scale | Standard Deviation 28.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C6D1 (n=120, 70) | 81.8 units on a scale | Standard Deviation 22.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C4D1 (n=134, 90) | 23.1 units on a scale | Standard Deviation 26.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C37D1 (n=1, 0) | 11.1 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C4D1 (n=135, 90) | 17.5 units on a scale | Standard Deviation 26 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C3D1 (n=154, 106) | 87.0 units on a scale | Standard Deviation 15.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C5D1 (n=123, 74) | 16.8 units on a scale | Standard Deviation 25 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: Baseline (n=165, 163) | 8.4 units on a scale | Standard Deviation 14.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C6D1 (n=120, 70) | 15.6 units on a scale | Standard Deviation 24 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C7D1 (n=115, 52) | 82.3 units on a scale | Standard Deviation 21.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C7D1 (n=115, 52) | 14.8 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C2D1 (n=155, 133) | 15.2 units on a scale | Standard Deviation 20.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C8D1 (n=111, 43) | 16.8 units on a scale | Standard Deviation 25 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C26D1 (n=14, 3) | 73.2 units on a scale | Standard Deviation 28.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C9D1 (n=101, 36) | 17.8 units on a scale | Standard Deviation 26.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C3D1 (n=154, 106) | 13.9 units on a scale | Standard Deviation 21.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C10D1 (n=94, 33) | 16.3 units on a scale | Standard Deviation 26.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C8D1 (n=111, 43) | 82.0 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C11D1 (n=84, 25) | 17.5 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C4D1 (n=135, 91) | 9.9 units on a scale | Standard Deviation 18.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C12D1 (n=76, 23) | 17.1 units on a scale | Standard Deviation 24.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C16D1 (n=53, 12) | 87.4 units on a scale | Standard Deviation 14.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C13D1 (n=74, 21) | 16.2 units on a scale | Standard Deviation 24.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C5D1 (n=123, 74) | 9.2 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C14D1 (n=66, 19) | 14.1 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C7D1 (n=115, 52) | 7.1 units on a scale | Standard Deviation 11.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C15D1 (n=62, 16) | 14.0 units on a scale | Standard Deviation 23 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C9D1 (n=101, 37) | 80.4 units on a scale | Standard Deviation 24.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C16D1 (n=53, 12) | 15.7 units on a scale | Standard Deviation 25 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C8D1 (n=111, 43) | 8.8 units on a scale | Standard Deviation 13.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C17D1 (n=47, 11) | 17.7 units on a scale | Standard Deviation 29.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C19D1 (n=40, 9) | 87.3 units on a scale | Standard Deviation 16 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C18D1 (n=44, 11) | 18.9 units on a scale | Standard Deviation 30 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C9D1 (n=101, 37) | 6.9 units on a scale | Standard Deviation 13 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C19D1 (n=40, 9) | 17.5 units on a scale | Standard Deviation 31.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C10D1 (n=94, 33) | 81.9 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C20D1 (n=35, 8) | 16.2 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C10D1 (n=94, 33) | 8.5 units on a scale | Standard Deviation 14.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C21D1 (n=30, 8) | 13.3 units on a scale | Standard Deviation 27.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C17D1 (n=47, 11) | 85.1 units on a scale | Standard Deviation 15.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C22D1 (n=24, 7) | 18.1 units on a scale | Standard Deviation 31.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C11D1 (n=84, 25) | 8.3 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C23D1 (n=23, 4) | 17.4 units on a scale | Standard Deviation 31.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C11D1 (n=84, 25) | 81.9 units on a scale | Standard Deviation 23 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C24D1 (n=20, 3) | 20.0 units on a scale | Standard Deviation 33.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C13D1 (n=74, 21) | 8.6 units on a scale | Standard Deviation 14.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C25D1 (n=18, 3) | 11.1 units on a scale | Standard Deviation 16.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C27D1 (n=14, 2) | 70.8 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C26D1 (n=14, 3) | 14.3 units on a scale | Standard Deviation 17.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C14D1 (n=66, 19) | 5.8 units on a scale | Standard Deviation 13.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C27D1 (n=14, 2) | 14.3 units on a scale | Standard Deviation 17.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C12D1 (n=76, 23) | 82.0 units on a scale | Standard Deviation 23.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C28D1 (n=11, 2) | 15.2 units on a scale | Standard Deviation 22.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C18D1 (n=44, 11) | 88.3 units on a scale | Standard Deviation 14.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C35D1 (n=4, 0) | 16.7 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C29D1 (n=8, 2) | 10.4 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C13D1 (n=74, 21) | 81.8 units on a scale | Standard Deviation 24.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C30D1 (n=8, 1) | 6.3 units on a scale | Standard Deviation 12.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: EOT (n=49, 90) | 21.8 units on a scale | Standard Deviation 26 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C12D1 (n=76, 23) | 85.3 units on a scale | Standard Deviation 18.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global Qol: EOT (n=49, 90) | 56.1 units on a scale | Standard Deviation 24.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C31D1 (n=7, 0) | 14.3 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: EOT (n=49, 90) | 80.7 units on a scale | Standard Deviation 23 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C14D1 (n=66, 19) | 81.3 units on a scale | Standard Deviation 23.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: EOT (n=49, 90) | 71.8 units on a scale | Standard Deviation 27.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C32D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: EOT (n=49, 90) | 75.2 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C19D1 (n=40, 9) | 87.5 units on a scale | Standard Deviation 14.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: EOT (n=49, 90) | 83.7 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C33D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Function: EOT (n=49, 90) | 78.2 units on a scale | Standard Deviation 27.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C15D1 (n=62, 16) | 81.5 units on a scale | Standard Deviation 25.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: EOT (n=49, 90) | 32.0 units on a scale | Standard Deviation 28.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C34D1 (n=5, 0) | 13.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: EOT (n=49, 90) | 16.3 units on a scale | Standard Deviation 22.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C28D1 (n=11, 2) | 81.1 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: EOT (n=49, 90) | 23.8 units on a scale | Standard Deviation 30.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C35D1 (n=4, 0) | 12.5 units on a scale | Standard Deviation 16 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: Baseline (n=165, 162) | 57.2 units on a scale | Standard Deviation 21.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C16D1 (n=53, 12) | 82.7 units on a scale | Standard Deviation 21.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C2D1 (n=154, 133) | 64.5 units on a scale | Standard Deviation 21.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C3D1 (n=154, 106) | 65.2 units on a scale | Standard Deviation 22.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C20D1 (n=35, 8) | 85.7 units on a scale | Standard Deviation 15.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C4D1 (n=135, 90) | 68.4 units on a scale | Standard Deviation 19.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C5D1 (n=123, 74) | 68.5 units on a scale | Standard Deviation 20.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C17D1 (n=47, 11) | 81.9 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C6D1 (n=120, 70) | 68.3 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: Baseline (n=165, 163) | 23.9 units on a scale | Standard Deviation 24.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C7D1 (n=114, 52) | 69.5 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C20D1 (n=35, 8) | 83.8 units on a scale | Standard Deviation 17.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C8D1 (n=110, 43) | 68.7 units on a scale | Standard Deviation 20.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C2D1 (n=155, 133) | 13.9 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C9D1 (n=101, 37) | 68.7 units on a scale | Standard Deviation 21 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C18D1 (n=44, 11) | 82.6 units on a scale | Standard Deviation 22.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C10D1 (n=94, 33) | 67.0 units on a scale | Standard Deviation 21.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C3D1 (n=154, 106) | 13.7 units on a scale | Standard Deviation 20.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C11D1 (n=83, 25) | 69.5 units on a scale | Standard Deviation 20.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C21D1 (n=30, 8) | 85.6 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C12D1 (n=76, 23) | 67.9 units on a scale | Standard Deviation 22 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C4D1 (n=135, 91) | 13.0 units on a scale | Standard Deviation 19.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C13D1 (n=74, 21) | 66.8 units on a scale | Standard Deviation 23.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C18D1 (n=45, 11) | 11.1 units on a scale | Standard Deviation 18.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C14D1 (n=66, 19) | 71.5 units on a scale | Standard Deviation 20 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C19D1 (n=40, 9) | 84.6 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C15D1 (n=62, 16) | 69.0 units on a scale | Standard Deviation 22.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C19D1 (n=40, 9) | 11.3 units on a scale | Standard Deviation 17 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C16D1 (n=53, 12) | 69.7 units on a scale | Standard Deviation 18.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C29D1 (n=8, 2) | 86.5 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C17D1 (n=47, 11) | 67.6 units on a scale | Standard Deviation 20.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C20D1 (n=35, 8) | 11.9 units on a scale | Standard Deviation 18.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C18D1 (n=44, 11) | 65.7 units on a scale | Standard Deviation 19.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C20D1 (n=35, 8) | 82.9 units on a scale | Standard Deviation 23.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C19D1 (n=40, 9) | 69.2 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C21D1 (n=30, 8) | 11.7 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C20D1 (n=35, 8) | 64.3 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C22D1 (n=24, 7) | 86.1 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C21D1 (n=30, 8) | 65.0 units on a scale | Standard Deviation 18.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C22D1 (n=24, 7) | 6.9 units on a scale | Standard Deviation 12.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C22D1 (n=24, 7) | 70.8 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C21D1 (n=30, 8) | 82.8 units on a scale | Standard Deviation 24.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C23D1 (n=23, 4) | 67.0 units on a scale | Standard Deviation 22.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C23D1 (n=23, 4) | 9.1 units on a scale | Standard Deviation 16.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C24D1 (n=20, 3) | 67.1 units on a scale | Standard Deviation 18.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C16D1 (n=53, 12) | 85.8 units on a scale | Standard Deviation 17.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C25D1 (n=18, 3) | 67.1 units on a scale | Standard Deviation 17.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C24D1 (n=20, 3) | 4.2 units on a scale | Standard Deviation 11.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C26D1 (n=14, 3) | 60.7 units on a scale | Standard Deviation 22 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C22D1 (n=24, 7) | 82.6 units on a scale | Standard Deviation 23.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C27D1 (n=14, 2) | 58.9 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C25D1 (n=18, 3) | 4.6 units on a scale | Standard Deviation 7.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C28D1 (n=11, 2) | 66.7 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C23D1 (n=23, 4) | 85.5 units on a scale | Standard Deviation 14.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C29D1 (n=8, 2) | 59.4 units on a scale | Standard Deviation 18.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C26D1 (n=14, 3) | 17.9 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C30D1 (n=8, 1) | 64.6 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C23D1 (n=23, 4) | 84.4 units on a scale | Standard Deviation 23.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C31D1 (n=7, 0) | 64.3 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C27D1 (n=14, 2) | 13.1 units on a scale | Standard Deviation 25.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C32D1 (n=6, 0) | 59.7 units on a scale | Standard Deviation 17 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C30D1 (n=8, 1) | 84.4 units on a scale | Standard Deviation 25 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C33D1 (n=6, 0) | 66.7 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C28D1 (n=11, 2) | 4.5 units on a scale | Standard Deviation 7.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C34D1 (n=5, 0) | 68.3 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C24D1 (n=20, 3) | 84.2 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C35D1 (n=4, 0) | 60.4 units on a scale | Standard Deviation 22.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C29D1 (n=8, 2) | 2.1 units on a scale | Standard Deviation 5.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C36D1 (n=1, 0) | 66.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C11D1 (n=84,25) | 86.1 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C8D1 (n=111, 43) | 18.6 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C23D1 (n=23, 4) | 5.4 units on a scale | Standard Deviation 10.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C9D1 (n=101, 37) | 17.3 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C33D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C10D1 (n=94, 33) | 17.7 units on a scale | Standard Deviation 22.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C12D1 (n=76, 23) | 89.5 units on a scale | Standard Deviation 14.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C11D1 (n=84, 25) | 21.0 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C34D1 (n=5, 0) | 13.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C12D1 (n=76, 23) | 17.5 units on a scale | Standard Deviation 25.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C24D1 (n=20, 3) | 7.5 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C13D1 (n=74, 21) | 17.6 units on a scale | Standard Deviation 23.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C35D1 (n=4, 0) | 16.7 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C14D1 (n=66, 19) | 17.7 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C23D1 (n=23, 4) | 25.1 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C15D1 (n=62, 16) | 16.1 units on a scale | Standard Deviation 21.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C16D1 (n=52, 12) | 16.0 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C25D1 (n=18, 3) | 3.7 units on a scale | Standard Deviation 9.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C17D1 (n=47, 11) | 19.9 units on a scale | Standard Deviation 22.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C18D1 (n=44, 11) | 22.7 units on a scale | Standard Deviation 25.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C8D1 (n=111, 43) | 87.8 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C19D1 (n=40, 9) | 21.7 units on a scale | Standard Deviation 25.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : Baseline (n=164, 163) | 22.6 units on a scale | Standard Deviation 26.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C20D1 (n=35, 8) | 21.0 units on a scale | Standard Deviation 24.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C26D1 (n=14, 3) | 10.7 units on a scale | Standard Deviation 27.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C21D1 (n=30, 8) | 22.2 units on a scale | Standard Deviation 22 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C2D1 (n=155, 133) | 15.3 units on a scale | Standard Deviation 23.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C22D1 (n=24, 7) | 23.6 units on a scale | Standard Deviation 25 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C24D1 (n=20, 3) | 24.4 units on a scale | Standard Deviation 18.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C23D1 (n=23, 4) | 15.9 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C3D1 (n=154, 106) | 16.2 units on a scale | Standard Deviation 26.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C24D1 (n=20, 3) | 21.7 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C27D1 (n=14, 2) | 11.9 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C25D1 (n=18, 3) | 20.4 units on a scale | Standard Deviation 25.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C4D1 (n=135, 91) | 13.3 units on a scale | Standard Deviation 21.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C26D1 (n=14, 3) | 19.0 units on a scale | Standard Deviation 25.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C13D1 (n=74, 21) | 88.5 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C27D1 (n=14, 2) | 23.8 units on a scale | Standard Deviation 30.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C5D1 (n=123, 74) | 13.6 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C28D1 (n=11, 2) | 15.2 units on a scale | Standard Deviation 17.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C28D1 (n=11, 2) | 3.0 units on a scale | Standard Deviation 6.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C29D1 (n=8, 2) | 20.8 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C6D1 (n=120, 70) | 14.2 units on a scale | Standard Deviation 21.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C30D1 (n=8, 1) | 12.5 units on a scale | Standard Deviation 17.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C25D1 (n=18, 3) | 24.7 units on a scale | Standard Deviation 16 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C31D1 (n=7, 0) | 14.3 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C7D1 (n=114, 52) | 9.4 units on a scale | Standard Deviation 17.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C32D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C5D1 (n=123, 74) | 11.5 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C33D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C8D1 (n=111, 43) | 12.5 units on a scale | Standard Deviation 21.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C34D1 (n=5, 0) | 6.7 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C6D1 (n=120, 70) | 87.5 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C35D1 (n=4, 0) | 16.7 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C9D1 (n=100, 37) | 12.3 units on a scale | Standard Deviation 21.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C36D1 (n=1, 0) | 33.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C6D1 (n=120, 70) | 10.6 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C37D1 (n=1, 0) | 33.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C10D1 (n=94, 33) | 13.5 units on a scale | Standard Deviation 23.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: EOT (n=49, 90) | 18.4 units on a scale | Standard Deviation 23.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C26D1 (n=14, 3) | 30.2 units on a scale | Standard Deviation 25.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: Baseline (n=165, 161) | 28.5 units on a scale | Standard Deviation 33 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C11D1 (n=84, 25) | 13.9 units on a scale | Standard Deviation 22.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C2D1 (n=155, 133) | 21.9 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C7D1 (n=115, 52) | 9.6 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C3D1 (n=154, 105) | 19.0 units on a scale | Standard Deviation 26.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C12D1 (n=76, 23) | 13.6 units on a scale | Standard Deviation 21.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C29D1 (n=8, 2) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C14D1 (n=66, 19) | 88.9 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C30D1 (n=8, 1) | 4.2 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C13D1 (n=74, 21) | 10.8 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C31D1 (n=7, 0) | 9.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C8D1 (n=111, 43) | 11.3 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C32D1 (n=6, 0) | 22.2 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C14D1 (n=66, 19) | 11.1 units on a scale | Standard Deviation 18.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C33D1 (n=6, 0) | 16.7 units on a scale | Standard Deviation 27.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C27D1 (n=14, 2) | 35.7 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C34D1 (n=5, 0) | 13.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C15D1 (n=62, 16) | 11.3 units on a scale | Standard Deviation 20 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C35D1 (n=4, 0) | 8.3 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C9D1 (n=101, 37) | 11.8 units on a scale | Standard Deviation 18.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C36D1 (n=1, 0) | 33.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C16D1 (n=53, 11) | 13.8 units on a scale | Standard Deviation 20.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C37D1 (n=1, 0) | 66.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C9D1 (n=101, 37) | 88.3 units on a scale | Standard Deviation 16.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: EOT (n=49, 90) | 17.0 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C17D1 (n=47, 11) | 13.5 units on a scale | Standard Deviation 21.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C32D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C10D1 (n=94, 33) | 8.7 units on a scale | Standard Deviation 14 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C33D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C31D1 (n=7, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C34D1 (n=5, 0) | 13.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: EOT (n=49, 90) | 23.8 units on a scale | Standard Deviation 28.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C28D1 (n=11, 2) | 28.3 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia: EOT (n=49, 90) | 18.4 units on a scale | Standard Deviation 24.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C32D1 (n=6, 0) | 5.6 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C37D1 (n=1, 0) | 66.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C11D1 (n=84, 25) | 10.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: Baseline (n=165, 163) | 76.3 units on a scale | Standard Deviation 20.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C33D1 (n=6, 0) | 5.6 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C2D1 (n=155, 133) | 79.2 units on a scale | Standard Deviation 20.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C15D1 (n=62, 16) | 87.6 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C3D1 (n=154, 106) | 82.3 units on a scale | Standard Deviation 18.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C34D1 (n=5, 0) | 13.3 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C4D1 (n=135, 91) | 83.8 units on a scale | Standard Deviation 16.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C12D1 (n=76, 23) | 8.6 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C5D1 (n=123, 74) | 84.5 units on a scale | Standard Deviation 16.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C35D1 (n=4, 0) | 16.7 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C6D1 (n=120, 70) | 86.2 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C29D1 (n=8, 2) | 30.6 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C7D1 (n=115, 52) | 86.7 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C8D1 (n=111, 43) | 86.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C13D1 (n=74, 21) | 10.1 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C9D1 (n=101, 37) | 87.7 units on a scale | Standard Deviation 14.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C10D1 (n=94, 33) | 87.9 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C5D1 (n=123, 74) | 88.9 units on a scale | Standard Deviation 14.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C11D1 (n=84, 25) | 87.2 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : Baseline(n=165, 163) | 24.4 units on a scale | Standard Deviation 28.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C12D1 (n=76, 23) | 88.1 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C14D1 (n=66, 19) | 8.1 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C13D1 (n=74, 21) | 89.3 units on a scale | Standard Deviation 13.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C2/D1(n=155, 133) | 21.1 units on a scale | Standard Deviation 30.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C14D1 (n=66, 19) | 89.0 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C12D1 (n=76, 23) | 6.4 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C15D1 (n=62, 16) | 87.8 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C3/D1(n=154, 106) | 18.4 units on a scale | Standard Deviation 29 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C16D1 (n=53, 12) | 89.3 units on a scale | Standard Deviation 11.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C15D1 (n=62, 16) | 9.4 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C17D1 (n=47, 11) | 86.6 units on a scale | Standard Deviation 16.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C4/D1(n=135, 91) | 14.6 units on a scale | Standard Deviation 24.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C18D1 (n=45, 11) | 88.4 units on a scale | Standard Deviation 13.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C18D1 (n=45, 11) | 21.5 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C19D1 (n=40, 9) | 88.3 units on a scale | Standard Deviation 12.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C5/D1(n=123, 74) | 12.7 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C20D1 (n=35, 8) | 87.6 units on a scale | Standard Deviation 12.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C16D1 (n=53, 12) | 9.4 units on a scale | Standard Deviation 14.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C21D1 (n=30, 8) | 88.4 units on a scale | Standard Deviation 10.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C6/D1(n=120, 70) | 13.6 units on a scale | Standard Deviation 21.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C22D1 (n=24, 7) | 90.6 units on a scale | Standard Deviation 8.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C15D1 (n=62, 16) | 5.9 units on a scale | Standard Deviation 11.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C23D1 (n=23, 4) | 88.0 units on a scale | Standard Deviation 13.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C7/D1(n=115, 52) | 10.4 units on a scale | Standard Deviation 19.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C24D1 (n=20, 3) | 85.0 units on a scale | Standard Deviation 14 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C17D1 (n=47, 11) | 10.6 units on a scale | Standard Deviation 16.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C25D1 (n=18, 3) | 87.4 units on a scale | Standard Deviation 11.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C23/D1(n=23, 4) | 9.4 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C26D1 (n=14, 3) | 80.5 units on a scale | Standard Deviation 25.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C10D1 (n=94, 33) | 89.2 units on a scale | Standard Deviation 16 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C27D1 (n=14, 2) | 78.6 units on a scale | Standard Deviation 27.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C24/D1(n=20, 3) | 5.0 units on a scale | Standard Deviation 12.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C28D1 (n=11, 2) | 81.8 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C2D1 (n=155, 133) | 21.5 units on a scale | Standard Deviation 21.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C29D1 (n=8, 2) | 85.0 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C25/D1(n=18, 3) | 1.9 units on a scale | Standard Deviation 7.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C30D1 (n=8, 1) | 82.5 units on a scale | Standard Deviation 21.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C16D1 (n=53, 12) | 5.3 units on a scale | Standard Deviation 9.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C31D1 (n=7, 0) | 83.8 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C26/D1(n=14, 3) | 11.9 units on a scale | Standard Deviation 21.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C32D1 (n=6, 0) | 88.9 units on a scale | Standard Deviation 9.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C3D1 (n=154, 106) | 21.6 units on a scale | Standard Deviation 23 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C33D1 (n=6, 0) | 90.0 units on a scale | Standard Deviation 7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C27/D1(n=14, 2) | 7.1 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C34D1 (n=5, 0) | 85.3 units on a scale | Standard Deviation 7.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C19D1 (n=40, 9) | 20.8 units on a scale | Standard Deviation 18.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C35D1 (n=4, 0) | 91.7 units on a scale | Standard Deviation 3.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C28/D1(n=11, 2) | 15.2 units on a scale | Standard Deviation 17.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C36D1 (n=1, 0) | 86.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C4D1 (n=135, 91) | 17.3 units on a scale | Standard Deviation 20.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C37D1 (n=1, 0) | 86.7 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C29/D1(n=8, 2) | 12.5 units on a scale | Standard Deviation 17.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: Baseline (n=165, 163) | 69.3 units on a scale | Standard Deviation 28.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C17D1 (n=47, 11) | 7.8 units on a scale | Standard Deviation 12.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C2D1 (n=155, 133) | 73.8 units on a scale | Standard Deviation 28.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C30/D1(n=8, 1) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C3D1 (n=154, 106) | 74.4 units on a scale | Standard Deviation 28.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C5D1 (n=123, 74) | 16.0 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C4D1 (n=134, 91) | 77.9 units on a scale | Standard Deviation 25.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C31/D1(n=7, 0) | 14.3 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C5D1 (n=123, 74) | 78.2 units on a scale | Standard Deviation 24.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C7D1 (n=115, 52) | 86.7 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C6D1 (n=120, 70) | 80.0 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: Baseline (n=164, 162) | 14.8 units on a scale | Standard Deviation 25.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C7D1 (n=115, 52) | 81.7 units on a scale | Standard Deviation 22.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C6D1 (n=120, 70) | 15.8 units on a scale | Standard Deviation 22 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C8D1 (n=111, 43) | 80.4 units on a scale | Standard Deviation 23.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C2D1 (n=155, 133) | 28.6 units on a scale | Standard Deviation 30.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C9D1 (n=101, 37) | 80.9 units on a scale | Standard Deviation 25.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C18D1 (n=45, 11) | 7.0 units on a scale | Standard Deviation 13.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C10D1 (n=94, 33) | 81.6 units on a scale | Standard Deviation 23.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C3D1 (n=154, 106) | 27.1 units on a scale | Standard Deviation 30 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C11D1 (n=84, 25) | 81.3 units on a scale | Standard Deviation 23.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C20D1 (n=35, 8) | 24.4 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C12D1 (n=76, 23) | 81.6 units on a scale | Standard Deviation 23.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C4D1 (n=134, 90) | 22.9 units on a scale | Standard Deviation 26.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C13D1 (n=74, 21) | 80.2 units on a scale | Standard Deviation 25.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C11D1 (n=84, 25) | 17.5 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C14D1 (n=66, 19) | 83.8 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C5D1 (n=123, 74) | 21.4 units on a scale | Standard Deviation 25.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C15D1 (n=62, 16) | 80.6 units on a scale | Standard Deviation 24 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C19D1 (n=40, 9) | 8.8 units on a scale | Standard Deviation 14.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C16D1 (n=53, 12) | 84.0 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C6D1 (n=120, 70) | 21.7 units on a scale | Standard Deviation 23.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C17D1 (n=47, 11) | 77.7 units on a scale | Standard Deviation 25.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C12D1 (n=76, 23) | 14.5 units on a scale | Standard Deviation 19.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C18D1 (n=45, 11) | 80.0 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C7D1 (n=115, 52) | 21.7 units on a scale | Standard Deviation 26.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C19D1 (n=40, 9) | 82.1 units on a scale | Standard Deviation 19.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C11D1 (n=84, 25) | 87.9 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C20D1 (n=35, 8) | 81.9 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C8D1 (n=111, 43) | 18.6 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C21D1 (n=30, 8) | 80.0 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C13D1 (n=74, 21) | 14.0 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C22D1 (n=24, 7) | 84.7 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C9D1 (n=101, 37) | 18.8 units on a scale | Standard Deviation 22.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C23D1 (n=23, 4) | 76.8 units on a scale | Standard Deviation 26.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C20D1 (n=35, 8) | 7.4 units on a scale | Standard Deviation 13.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C24D1 (n=20, 3) | 80.8 units on a scale | Standard Deviation 24.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C10D1 (n=94, 33) | 16.0 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C25D1 (n=18, 3) | 87.0 units on a scale | Standard Deviation 19.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C14D1 (n=66, 19) | 15.2 units on a scale | Standard Deviation 21.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C26D1 (n=14, 3) | 75.0 units on a scale | Standard Deviation 29.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C11D1 (n=84, 25) | 21.0 units on a scale | Standard Deviation 25.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C27D1 (n=14, 2) | 69.0 units on a scale | Standard Deviation 35.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C21D1 (n=30, 8) | 23.9 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C28D1 (n=11, 2) | 77.3 units on a scale | Standard Deviation 33.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C12D1 (n=76, 23) | 19.7 units on a scale | Standard Deviation 24.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C29D1 (n=8, 2) | 77.1 units on a scale | Standard Deviation 34.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C15D1 (n=62, 16) | 15.6 units on a scale | Standard Deviation 21.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C30D1 (n=8, 1) | 77.1 units on a scale | Standard Deviation 34.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C13D1 (n=74, 21) | 21.2 units on a scale | Standard Deviation 26.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C31D1 (n=7, 0) | 71.4 units on a scale | Standard Deviation 36.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C21D1 (n=30, 8) | 7.8 units on a scale | Standard Deviation 12.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C32D1 (n=6, 0) | 86.1 units on a scale | Standard Deviation 12.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C14D1 (n=66, 19) | 21.7 units on a scale | Standard Deviation 27.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C33D1 (n=6, 0) | 88.9 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C16D1 (n=53, 12) | 13.8 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C34D1 (n=5, 0) | 96.7 units on a scale | Standard Deviation 7.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C15D1 (n=62, 16) | 22.6 units on a scale | Standard Deviation 27.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C35D1 (n=4, 0) | 91.7 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C4D1 (n=135, 90) | 88.1 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C36D1 (n=1, 0) | 100.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C16D1 (n=53, 12) | 19.5 units on a scale | Standard Deviation 26.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C37D1 (n=1, 0) | 100.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C17D1 (n=46, 11) | 14.5 units on a scale | Standard Deviation 20.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: Baseline (n=165, 162) | 74.5 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C17D1 (n=47, 11) | 22.0 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C2D1 (n=155, 133) | 83.1 units on a scale | Standard Deviation 18.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C22D1 (n=24, 7) | 2.8 units on a scale | Standard Deviation 6.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C3D1 (n=154, 106) | 83.3 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C18D1 (n=44, 11) | 22.7 units on a scale | Standard Deviation 25.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C4D1 (n=135, 90) | 84.1 units on a scale | Standard Deviation 17.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C18D1 (n=45, 11) | 14.1 units on a scale | Standard Deviation 16.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C5D1 (n=123, 74) | 83.0 units on a scale | Standard Deviation 19.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C5D1 (n=123, 74) | 24.4 units on a scale | Standard Deviation 25.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C6D1 (n=120, 70) | 85.3 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C31D1 (n=7, 0) | 9.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C7D1 (n=115, 52) | 86.4 units on a scale | Standard Deviation 16.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C6D1 (n=120, 70) | 22.2 units on a scale | Standard Deviation 26.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C8D1 (n=111, 43) | 83.9 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C22D1 (n=24, 7) | 23.6 units on a scale | Standard Deviation 16.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C9D1 (n=101, 37) | 84.4 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C7D1 (n=115, 52) | 20.6 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C10D1 (n=94, 33) | 87.2 units on a scale | Standard Deviation 16.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C32D1 (n=6, 0) | 16.7 units on a scale | Standard Deviation 18.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C10D1 (n=94, 33) | 81.8 units on a scale | Standard Deviation 21.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C4D1 (n=135, 90) | 82.6 units on a scale | Standard Deviation 20.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C5D1 (n=123, 74) | 82.7 units on a scale | Standard Deviation 22 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C6D1 (n=120, 70) | 83.8 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C7D1 (n=115, 52) | 85.3 units on a scale | Standard Deviation 18.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C8D1 (n=111, 43) | 82.2 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C9D1 (n=101, 37) | 84.7 units on a scale | Standard Deviation 21.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C10D1 (n=94, 33) | 80.8 units on a scale | Standard Deviation 22.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C11D1 (n=84, 25) | 85.3 units on a scale | Standard Deviation 19.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C12D1 (n=76, 23) | 80.4 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C13D1 (n=74, 21) | 79.4 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C14D1 (n=66, 19) | 81.6 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C17D1 (n=47, 11) | 23.2 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C18D1 (n=45, 11) | 27.3 units on a scale | Standard Deviation 22.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C19D1 (n=40, 9) | 24.7 units on a scale | Standard Deviation 20.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C20D1 (n=35, 8) | 27.8 units on a scale | Standard Deviation 26.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C21D1 (n=30, 8) | 25.7 units on a scale | Standard Deviation 27.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C22D1 (n=24, 7) | 27.0 units on a scale | Standard Deviation 23.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C23D1 (n=23, 4) | 47.2 units on a scale | Standard Deviation 14 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C24D1 (n=20, 3) | 40.7 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C26D1 (n=14, 3) | 44.4 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C27D1 (n=14, 2) | 55.6 units on a scale | Standard Deviation 15.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C28D1 (n=11, 2) | 38.9 units on a scale | Standard Deviation 7.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C29D1 (n=8, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C12D1 (n=76, 23) | 7.2 units on a scale | Standard Deviation 15.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C15D1 (n=62, 16) | 6.2 units on a scale | Standard Deviation 13.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C16D1 (n=53, 12) | 6.9 units on a scale | Standard Deviation 11.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C17D1 (n=47, 11) | 10.6 units on a scale | Standard Deviation 11.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C18D1 (n=45, 11) | 3.0 units on a scale | Standard Deviation 6.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C19D1 (n=40, 9) | 9.3 units on a scale | Standard Deviation 12.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C20D1 (n=35, 8) | 10.4 units on a scale | Standard Deviation 15.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C21D1 (n=30, 8) | 8.3 units on a scale | Standard Deviation 12.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C22D1 (n=24, 7) | 14.3 units on a scale | Standard Deviation 17.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C23D1 (n=23, 4) | 45.8 units on a scale | Standard Deviation 21 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C24D1 (n=20, 3) | 33.3 units on a scale | Standard Deviation 28.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C25D1 (n=18, 3) | 27.8 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C26D1 (n=14, 3) | 33.3 units on a scale | Standard Deviation 16.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C27D1 (n=14, 2) | 33.3 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C4D1 (n=135, 91) | 19.0 units on a scale | Standard Deviation 21.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C5D1 (n=123, 74) | 20.5 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C6D1 (n=120, 70) | 19.5 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C7D1 (n=115, 52) | 21.5 units on a scale | Standard Deviation 24.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C8D1 (n=111, 43) | 17.4 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C9D1 (n=101, 37) | 23.0 units on a scale | Standard Deviation 27.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C10D1 (n=94, 33) | 24.2 units on a scale | Standard Deviation 28.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C11D1 (n=84, 25) | 22.0 units on a scale | Standard Deviation 27.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C12D1 (n=76, 23) | 25.4 units on a scale | Standard Deviation 29.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C13D1 (n=74, 21) | 27.8 units on a scale | Standard Deviation 30.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C14D1 (n=66, 19) | 23.7 units on a scale | Standard Deviation 26.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C15D1 (n=62, 16) | 22.9 units on a scale | Standard Deviation 25.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C16D1 (n=53, 12) | 31.9 units on a scale | Standard Deviation 28.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C17D1 (n=47, 11) | 24.2 units on a scale | Standard Deviation 27.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C2D1 (n=155, 133) | 33.6 units on a scale | Standard Deviation 27.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C3D1 (n=154, 106) | 33.3 units on a scale | Standard Deviation 28.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C4D1 (n=135, 91) | 29.3 units on a scale | Standard Deviation 26.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C5D1 (n=123, 74) | 29.3 units on a scale | Standard Deviation 24 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C6D1 (n=120, 70) | 26.2 units on a scale | Standard Deviation 24.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C10D1 (n=94, 33) | 24.2 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C11D1 (n=84, 25) | 25.3 units on a scale | Standard Deviation 22.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C12D1 (n=76, 23) | 30.4 units on a scale | Standard Deviation 28.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C13D1 (n=74, 21) | 23.8 units on a scale | Standard Deviation 23.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C14D1 (n=66, 19) | 29.8 units on a scale | Standard Deviation 24.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C15D1 (n=62, 16) | 20.8 units on a scale | Standard Deviation 20.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C16D1 (n=53, 12) | 19.4 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C17D1 (n=46, 11) | 24.2 units on a scale | Standard Deviation 21.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : Baseline (n=164, 163) | 27.8 units on a scale | Standard Deviation 27.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C2D1 (n=155, 133) | 27.1 units on a scale | Standard Deviation 25.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C3D1 (n=154, 106) | 23.6 units on a scale | Standard Deviation 26 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C4D1 (n=135, 91) | 23.8 units on a scale | Standard Deviation 26.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C5D1 (n=123, 74) | 25.7 units on a scale | Standard Deviation 26.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C6D1 (n=120, 70) | 23.3 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C7D1 (n=114, 52) | 21.8 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C8D1 (n=111, 43) | 21.7 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C9D1 (n=100, 37) | 22.5 units on a scale | Standard Deviation 24.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C10D1 (n=94, 33) | 24.2 units on a scale | Standard Deviation 25.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C11D1 (n=84, 25) | 22.7 units on a scale | Standard Deviation 24.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C12D1 (n=76, 23) | 23.2 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C13D1 (n=74, 21) | 25.4 units on a scale | Standard Deviation 25.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C14D1 (n=66, 19) | 24.6 units on a scale | Standard Deviation 29.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C15D1 (n=62, 16) | 29.2 units on a scale | Standard Deviation 26.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C16D1 (n=53, 11) | 21.2 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C17D1 (n=47, 11) | 15.2 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : Baseline(n=165, 163) | 23.3 units on a scale | Standard Deviation 28.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C2/D1(n=155, 133) | 24.3 units on a scale | Standard Deviation 28.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C3/D1(n=154, 106) | 21.7 units on a scale | Standard Deviation 27.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C4/D1(n=135, 91) | 19.4 units on a scale | Standard Deviation 23.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C5/D1(n=123, 74) | 19.4 units on a scale | Standard Deviation 28.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C6/D1(n=120, 70) | 12.9 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C22/D1(n=24, 7) | 14.3 units on a scale | Standard Deviation 37.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C23/D1(n=23, 4) | 50.0 units on a scale | Standard Deviation 43 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C24/D1(n=20, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C25/D1(n=18, 3) | 44.4 units on a scale | Standard Deviation 50.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C26/D1(n=14, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C27/D1(n=14, 2) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C28/D1(n=11, 2) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C29/D1(n=8, 2) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C30/D1(n=8, 1) | 100.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C31/D1(n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: Baseline (n=164, 162) | 16.9 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C2D1 (n=155, 133) | 14.0 units on a scale | Standard Deviation 24.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C3D1 (n=154, 106) | 16.0 units on a scale | Standard Deviation 22.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C4D1 (n=134, 90) | 14.8 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C5D1 (n=123, 74) | 20.3 units on a scale | Standard Deviation 29.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C6D1 (n=120, 70) | 15.7 units on a scale | Standard Deviation 23.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C7D1 (n=115, 52) | 19.9 units on a scale | Standard Deviation 26.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C8D1 (n=111, 43) | 16.3 units on a scale | Standard Deviation 24.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C9D1 (n=101, 37) | 16.2 units on a scale | Standard Deviation 21.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C10D1 (n=94, 33) | 19.2 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C11D1 (n=84, 25) | 21.3 units on a scale | Standard Deviation 19 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C12D1 (n=76, 23) | 21.7 units on a scale | Standard Deviation 23.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C13D1 (n=74, 21) | 22.2 units on a scale | Standard Deviation 26.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C14D1 (n=66, 19) | 24.6 units on a scale | Standard Deviation 31.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C15D1 (n=62, 16) | 18.7 units on a scale | Standard Deviation 21 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C16D1 (n=53, 12) | 22.2 units on a scale | Standard Deviation 25.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C17D1 (n=47, 11) | 24.2 units on a scale | Standard Deviation 30.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C4D1 (n=134, 90) | 8.5 units on a scale | Standard Deviation 18.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C5D1 (n=123, 74) | 5.9 units on a scale | Standard Deviation 15 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C6D1 (n=120, 70) | 7.1 units on a scale | Standard Deviation 16.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C7D1 (n=115, 52) | 9.6 units on a scale | Standard Deviation 16.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C8D1 (n=111, 43) | 9.3 units on a scale | Standard Deviation 19.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C9D1 (n=101, 37) | 7.2 units on a scale | Standard Deviation 16 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C10D1 (n=94, 33) | 7.1 units on a scale | Standard Deviation 16.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C11D1 (n=84, 25) | 8.0 units on a scale | Standard Deviation 17.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C12D1 (n=76, 23) | 8.7 units on a scale | Standard Deviation 15 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C13D1 (n=74, 21) | 12.7 units on a scale | Standard Deviation 19.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C14D1 (n=66, 19) | 8.8 units on a scale | Standard Deviation 18.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C15D1 (n=62, 16) | 4.2 units on a scale | Standard Deviation 11.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C16D1 (n=52, 12) | 5.6 units on a scale | Standard Deviation 13 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C17D1 (n=47, 11) | 12.1 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C18D1 (n=44, 11) | 12.1 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C19D1 (n=40, 9) | 7.4 units on a scale | Standard Deviation 14.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C20D1 (n=35, 8) | 4.2 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C21D1 (n=30, 8) | 8.3 units on a scale | Standard Deviation 15.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C22D1 (n=24, 7) | 11.9 units on a scale | Standard Deviation 15.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C23D1 (n=23, 4) | 25.0 units on a scale | Standard Deviation 16.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C24D1 (n=20, 3) | 11.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C25D1 (n=18, 3) | 22.2 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C26D1 (n=14, 3) | 11.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C27D1 (n=14, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C28D1 (n=11, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C29D1 (n=8, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C30D1 (n=8, 1) | 0.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: EOT (n=49, 90) | 10.0 units on a scale | Standard Deviation 21.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: Baseline (n=165, 161) | 27.3 units on a scale | Standard Deviation 30.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C2D1 (n=155, 133) | 22.3 units on a scale | Standard Deviation 28.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C28D1 (n=11, 2) | 66.7 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C29D1 (n=8, 2) | 66.7 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C30D1 (n=8, 1) | 100.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: EOT (n=49, 90) | 24.1 units on a scale | Standard Deviation 30 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: EOT (n=49, 90) | 40.0 units on a scale | Standard Deviation 30.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia: EOT (n=49, 90) | 30.4 units on a scale | Standard Deviation 27.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: Baseline (n=165, 163) | 75.8 units on a scale | Standard Deviation 21.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C2D1 (n=155, 133) | 73.5 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C3D1 (n=154, 106) | 75.5 units on a scale | Standard Deviation 20.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C4D1 (n=135, 91) | 76.6 units on a scale | Standard Deviation 20.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C5D1 (n=123, 74) | 78.6 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C6D1 (n=120, 70) | 80.7 units on a scale | Standard Deviation 19.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C7D1 (n=115, 52) | 80.3 units on a scale | Standard Deviation 19.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C8D1 (n=111, 43) | 81.6 units on a scale | Standard Deviation 18.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C9D1 (n=101, 37) | 82.3 units on a scale | Standard Deviation 19.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C10D1 (n=94, 33) | 81.8 units on a scale | Standard Deviation 20.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C11D1 (n=84, 25) | 83.2 units on a scale | Standard Deviation 19 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C12D1 (n=76, 23) | 79.7 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C13D1 (n=74, 21) | 78.4 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C14D1 (n=66, 19) | 80.0 units on a scale | Standard Deviation 21.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C15D1 (n=62, 16) | 82.9 units on a scale | Standard Deviation 15.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C16D1 (n=53, 12) | 81.1 units on a scale | Standard Deviation 19.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C17D1 (n=47, 11) | 81.8 units on a scale | Standard Deviation 15.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C18D1 (n=45, 11) | 82.4 units on a scale | Standard Deviation 16.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C19D1 (n=40, 9) | 81.5 units on a scale | Standard Deviation 12.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C20D1 (n=35, 8) | 79.2 units on a scale | Standard Deviation 17.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C21D1 (n=30, 8) | 77.5 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C22D1 (n=24, 7) | 78.1 units on a scale | Standard Deviation 24.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C23D1 (n=23, 4) | 60.0 units on a scale | Standard Deviation 27.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C24D1 (n=20, 3) | 64.4 units on a scale | Standard Deviation 32.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C25D1 (n=18, 3) | 60.0 units on a scale | Standard Deviation 29.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C26D1 (n=14, 3) | 62.2 units on a scale | Standard Deviation 30.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C28D1 (n=11, 2) | 60.0 units on a scale | Standard Deviation 18.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C29D1 (n=8, 2) | 46.7 units on a scale | Standard Deviation 28.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C30D1 (n=8, 1) | 26.7 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: Baseline (n=165, 163) | 66.6 units on a scale | Standard Deviation 30.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C2D1 (n=155, 133) | 64.7 units on a scale | Standard Deviation 29.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C3D1 (n=154, 106) | 65.3 units on a scale | Standard Deviation 27.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C4D1 (n=134, 91) | 67.2 units on a scale | Standard Deviation 27.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C5D1 (n=123, 74) | 69.6 units on a scale | Standard Deviation 27.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C6D1 (n=120, 70) | 69.5 units on a scale | Standard Deviation 26.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C7D1 (n=115, 52) | 72.1 units on a scale | Standard Deviation 25.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C8D1 (n=111, 43) | 75.2 units on a scale | Standard Deviation 28.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C9D1 (n=101, 37) | 76.6 units on a scale | Standard Deviation 27.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C10D1 (n=94, 33) | 75.3 units on a scale | Standard Deviation 28.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C11D1 (n=84, 25) | 75.3 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C12D1 (n=76, 23) | 72.5 units on a scale | Standard Deviation 29.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C13D1 (n=74, 21) | 68.3 units on a scale | Standard Deviation 32 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C14D1 (n=66, 19) | 68.4 units on a scale | Standard Deviation 30.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C15D1 (n=62, 16) | 77.1 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C16D1 (n=53, 12) | 69.4 units on a scale | Standard Deviation 34 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C17D1 (n=47, 11) | 71.2 units on a scale | Standard Deviation 38.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C18D1 (n=45, 11) | 71.2 units on a scale | Standard Deviation 31.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C19D1 (n=40, 9) | 74.1 units on a scale | Standard Deviation 29 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C20D1 (n=35, 8) | 70.8 units on a scale | Standard Deviation 36.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C21D1 (n=30, 8) | 66.7 units on a scale | Standard Deviation 32.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C22D1 (n=24, 7) | 67.9 units on a scale | Standard Deviation 33.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C23D1 (n=23, 4) | 37.5 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C24D1 (n=20, 3) | 44.4 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C26D1 (n=14, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C27D1 (n=14, 2) | 25.0 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C28D1 (n=11, 2) | 25.0 units on a scale | Standard Deviation 35.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C29D1 (n=8, 2) | 25.0 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C30D1 (n=8, 1) | 0.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: Baseline (n=165, 162) | 73.7 units on a scale | Standard Deviation 20.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C2D1 (n=155, 133) | 77.7 units on a scale | Standard Deviation 19.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C3D1 (n=154, 106) | 77.9 units on a scale | Standard Deviation 21.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C4D1 (n=135, 90) | 80.5 units on a scale | Standard Deviation 18.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C5D1 (n=123, 74) | 79.8 units on a scale | Standard Deviation 19.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C6D1 (n=120, 70) | 81.2 units on a scale | Standard Deviation 19.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C7D1 (n=115, 52) | 81.9 units on a scale | Standard Deviation 17.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C8D1 (n=111, 43) | 81.6 units on a scale | Standard Deviation 20.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C9D1 (n=101, 37) | 82.4 units on a scale | Standard Deviation 19.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C3D1 (n=154, 106) | 83.8 units on a scale | Standard Deviation 20.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C11D1 (n=84,25) | 85.0 units on a scale | Standard Deviation 17.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C12D1 (n=76, 23) | 84.8 units on a scale | Standard Deviation 18.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C13D1 (n=74, 21) | 80.6 units on a scale | Standard Deviation 19.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C14D1 (n=66, 19) | 81.6 units on a scale | Standard Deviation 21.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C15D1 (n=62, 16) | 82.3 units on a scale | Standard Deviation 18.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C16D1 (n=53, 12) | 77.8 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C17D1 (n=47, 11) | 79.5 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C18D1 (n=44, 11) | 75.8 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C19D1 (n=40, 9) | 81.5 units on a scale | Standard Deviation 20.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C20D1 (n=35, 8) | 82.3 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C21D1 (n=30, 8) | 80.2 units on a scale | Standard Deviation 29.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C22D1 (n=24, 7) | 78.6 units on a scale | Standard Deviation 24.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C23D1 (n=23, 4) | 70.8 units on a scale | Standard Deviation 21 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C24D1 (n=20, 3) | 66.7 units on a scale | Standard Deviation 30 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C25D1 (n=18, 3) | 72.2 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C26D1 (n=14, 3) | 72.2 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C27D1 (n=14, 2) | 58.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C28D1 (n=11, 2) | 58.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C29D1 (n=8, 2) | 54.2 units on a scale | Standard Deviation 5.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C30D1 (n=8, 1) | 58.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: Baseline (n=165, 162) | 83.6 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C2D1 (n=155, 133) | 84.5 units on a scale | Standard Deviation 20.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C15D1 (n=62, 16) | 84.4 units on a scale | Standard Deviation 18.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C16D1 (n=53, 12) | 72.2 units on a scale | Standard Deviation 25.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C17D1 (n=47, 11) | 75.8 units on a scale | Standard Deviation 21.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C18D1 (n=44, 11) | 75.8 units on a scale | Standard Deviation 25.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C19D1 (n=40, 9) | 70.4 units on a scale | Standard Deviation 23.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C20D1 (n=35, 8) | 72.9 units on a scale | Standard Deviation 23.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C21D1 (n=30, 8) | 72.9 units on a scale | Standard Deviation 23.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C22D1 (n=24, 7) | 69.0 units on a scale | Standard Deviation 24.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C23D1 (n=23, 4) | 58.3 units on a scale | Standard Deviation 21.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C24D1 (n=20, 3) | 61.1 units on a scale | Standard Deviation 34.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C25D1 (n=18, 3) | 55.6 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C26D1 (n=14, 3) | 61.1 units on a scale | Standard Deviation 34.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C27D1 (n=14, 2) | 41.7 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C28D1 (n=11, 2) | 41.7 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C29D1 (n=8, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C30D1 (n=8, 1) | 16.7 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: Baseline (n=165, 162) | 67.1 units on a scale | Standard Deviation 29 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C2D1 (n=155, 133) | 69.5 units on a scale | Standard Deviation 28.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C3D1 (n=154, 106) | 72.5 units on a scale | Standard Deviation 26.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C4D1 (n=135, 90) | 71.7 units on a scale | Standard Deviation 26.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C5D1 (n=123, 74) | 74.5 units on a scale | Standard Deviation 27.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C6D1 (n=120, 70) | 76.4 units on a scale | Standard Deviation 27.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C7D1 (n=115, 52) | 77.9 units on a scale | Standard Deviation 24.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C8D1 (n=111, 43) | 77.5 units on a scale | Standard Deviation 24.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C9D1 (n=101, 37) | 80.2 units on a scale | Standard Deviation 21.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C10D1 (n=94, 33) | 76.3 units on a scale | Standard Deviation 27 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C11D1 (n=84, 25) | 78.7 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C12D1 (n=76, 23) | 71.0 units on a scale | Standard Deviation 31.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C13D1 (n=74, 21) | 71.4 units on a scale | Standard Deviation 28.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C14D1 (n=66, 19) | 69.3 units on a scale | Standard Deviation 34.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C15D1 (n=62, 16) | 74.0 units on a scale | Standard Deviation 28.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C16D1 (n=53, 12) | 65.3 units on a scale | Standard Deviation 35.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C17D1 (n=47, 11) | 69.7 units on a scale | Standard Deviation 33.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C18D1 (n=44, 11) | 65.2 units on a scale | Standard Deviation 35.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C19D1 (n=40, 9) | 64.8 units on a scale | Standard Deviation 31.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C20D1 (n=35, 8) | 70.8 units on a scale | Standard Deviation 33 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C21D1 (n=30, 8) | 64.6 units on a scale | Standard Deviation 36.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C22D1 (n=24, 7) | 65.5 units on a scale | Standard Deviation 39.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C23D1 (n=23, 4) | 41.7 units on a scale | Standard Deviation 50 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C24D1 (n=20, 3) | 61.1 units on a scale | Standard Deviation 53.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C25D1 (n=18, 3) | 50.0 units on a scale | Standard Deviation 50 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C26D1 (n=14, 3) | 50.0 units on a scale | Standard Deviation 50 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C27D1 (n=14, 2) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C28D1 (n=11, 2) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C29D1 (n=8, 2) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C30D1 (n=8, 1) | 0.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Functioning: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: Baseline (n=165, 163) | 36.1 units on a scale | Standard Deviation 25.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C2D1 (n=155, 133) | 39.5 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C3D1 (n=154, 106) | 39.4 units on a scale | Standard Deviation 24.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C4D1 (n=135, 91) | 34.1 units on a scale | Standard Deviation 22.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C5D1 (n=123, 74) | 31.5 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C6D1 (n=120, 70) | 31.0 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C7D1 (n=115, 52) | 27.6 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C8D1 (n=111, 43) | 26.6 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C9D1 (n=101, 37) | 28.5 units on a scale | Standard Deviation 26.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C10D1 (n=94, 33) | 28.6 units on a scale | Standard Deviation 27.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C11D1 (n=84, 25) | 22.2 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C12D1 (n=76, 23) | 26.1 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C13D1 (n=74, 21) | 27.5 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C14D1 (n=66, 19) | 28.1 units on a scale | Standard Deviation 26.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C15D1 (n=62, 16) | 24.3 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C5D1 (n=123, 74) | 9.0 units on a scale | Standard Deviation 16.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C6D1 (n=120, 70) | 6.9 units on a scale | Standard Deviation 13.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C16D1 (n=53, 12) | 24.1 units on a scale | Standard Deviation 21.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C30D1 (n=8, 1) | 55.6 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: Baseline (n=165, 163) | 11.7 units on a scale | Standard Deviation 18 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C2D1 (n=155, 133) | 12.7 units on a scale | Standard Deviation 19 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C3D1 (n=154, 106) | 9.9 units on a scale | Standard Deviation 16.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C4D1 (n=135, 91) | 8.1 units on a scale | Standard Deviation 14.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C7D1 (n=115, 52) | 7.7 units on a scale | Standard Deviation 11.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C8D1 (n=111, 43) | 8.9 units on a scale | Standard Deviation 14.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C9D1 (n=101, 37) | 9.5 units on a scale | Standard Deviation 19.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C10D1 (n=94, 33) | 8.1 units on a scale | Standard Deviation 15.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C11D1 (n=84, 25) | 8.0 units on a scale | Standard Deviation 16 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C13D1 (n=74, 21) | 7.1 units on a scale | Standard Deviation 16.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C14D1 (n=66, 19) | 7.0 units on a scale | Standard Deviation 14 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C28D1 (n=11, 2) | 25.0 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C29D1 (n=8, 2) | 25.0 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: Baseline (n=165, 163) | 28.0 units on a scale | Standard Deviation 27.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C2D1 (n=155, 133) | 25.7 units on a scale | Standard Deviation 25.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C3D1 (n=154, 106) | 23.3 units on a scale | Standard Deviation 26.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C18D1 (n=45, 11) | 24.2 units on a scale | Standard Deviation 29.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C19D1 (n=40, 9) | 24.1 units on a scale | Standard Deviation 20.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C20D1 (n=35, 8) | 22.9 units on a scale | Standard Deviation 28.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C21D1 (n=30, 8) | 29.2 units on a scale | Standard Deviation 30.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C22D1 (n=24, 7) | 33.3 units on a scale | Standard Deviation 28.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C23D1 (n=23, 4) | 33.3 units on a scale | Standard Deviation 36 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C24D1 (n=20, 3) | 27.8 units on a scale | Standard Deviation 48.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C25D1 (n=18, 3) | 38.9 units on a scale | Standard Deviation 41.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C26D1 (n=14, 3) | 38.9 units on a scale | Standard Deviation 41.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C27D1 (n=14, 2) | 58.3 units on a scale | Standard Deviation 35.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C29D1 (n=8, 2) | 41.7 units on a scale | Standard Deviation 35.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C30D1 (n=8, 1) | 83.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: Baseline (n=165, 163) | 32.5 units on a scale | Standard Deviation 28.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C7D1 (n=115, 52) | 28.2 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C8D1 (n=111, 43) | 22.5 units on a scale | Standard Deviation 28.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C9D1 (n=101, 37) | 23.4 units on a scale | Standard Deviation 24.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C18D1 (n=45, 11) | 24.2 units on a scale | Standard Deviation 26.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C19D1 (n=40, 9) | 25.9 units on a scale | Standard Deviation 22.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C20D1 (n=35, 8) | 33.3 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C21D1 (n=30, 8) | 33.3 units on a scale | Standard Deviation 17.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C22D1 (n=24, 7) | 28.6 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C23D1 (n=23, 4) | 41.7 units on a scale | Standard Deviation 16.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C24D1 (n=20, 3) | 44.4 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C25D1 (n=18, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C26D1 (n=14, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C29D1 (n=8, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Dyspnea: C30D1 (n=8, 1) | 66.7 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C18D1 (n=45, 11) | 21.2 units on a scale | Standard Deviation 27 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C19D1 (n=40, 9) | 22.2 units on a scale | Standard Deviation 28.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C20D1 (n=35, 8) | 20.8 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C21D1 (n=30, 8) | 29.2 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C22D1 (n=24, 7) | 31.0 units on a scale | Standard Deviation 24.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C23D1 (n=23, 4) | 50.0 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C24D1 (n=20, 3) | 22.2 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C26D1 (n=14, 3) | 22.2 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C29D1 (n=8, 2) | 33.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Insomnia : C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C7/D1(n=115, 52) | 12.8 units on a scale | Standard Deviation 22 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C8/D1(n=111, 43) | 10.9 units on a scale | Standard Deviation 22.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C9/D1(n=101, 37) | 14.4 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C10/D1(n=94, 33) | 14.1 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C11/D1(n=84, 25) | 14.7 units on a scale | Standard Deviation 25.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C12/D1(n=76, 23) | 14.5 units on a scale | Standard Deviation 24.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C13/D1(n=74, 21) | 17.5 units on a scale | Standard Deviation 27.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C15/D1(n=62, 16) | 12.5 units on a scale | Standard Deviation 26.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C16/D1(n=53, 12) | 16.7 units on a scale | Standard Deviation 30.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C17/D1(n=47, 11) | 15.2 units on a scale | Standard Deviation 31.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C18/D1(n=45, 11) | 12.1 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C19/D1(n=40, 9) | 18.5 units on a scale | Standard Deviation 33.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C20/D1(n=35, 8) | 20.8 units on a scale | Standard Deviation 35.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss : C21/D1(n=30, 8) | 25.0 units on a scale | Standard Deviation 34.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C18D1 (n=44, 11) | 15.2 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C19D1 (n=40, 9) | 22.2 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C20D1 (n=35, 8) | 20.8 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C21D1 (n=30, 8) | 16.7 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C22D1 (n=24, 7) | 19.0 units on a scale | Standard Deviation 26.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C23D1 (n=23, 4) | 25.0 units on a scale | Standard Deviation 31.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C24D1 (n=20, 3) | 22.2 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C25D1 (n=18, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C26D1 (n=14, 3) | 44.4 units on a scale | Standard Deviation 50.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C29D1 (n=8, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Constipation: EOT (n=49, 90) | 18.1 units on a scale | Standard Deviation 25.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: Baseline (n=165, 162) | 7.8 units on a scale | Standard Deviation 16 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C2D1 (n=155, 132) | 11.1 units on a scale | Standard Deviation 20.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Diarrhea: C3D1 (n=153, 106) | 7.9 units on a scale | Standard Deviation 18.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C3D1 (n=154, 105) | 20.3 units on a scale | Standard Deviation 27.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C4D1 (n=135, 90) | 21.9 units on a scale | Standard Deviation 26 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C5D1 (n=123, 74) | 19.4 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C6D1 (n=120, 70) | 18.6 units on a scale | Standard Deviation 25.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C7D1 (n=115, 52) | 18.6 units on a scale | Standard Deviation 25.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C8D1 (n=111, 43) | 15.5 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C9D1 (n=101, 36) | 16.7 units on a scale | Standard Deviation 23.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C10D1 (n=94, 33) | 15.2 units on a scale | Standard Deviation 23.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C11D1 (n=84, 25) | 17.3 units on a scale | Standard Deviation 21.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C12D1 (n=76, 23) | 18.8 units on a scale | Standard Deviation 28.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C13D1 (n=74, 21) | 17.5 units on a scale | Standard Deviation 27.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C14D1 (n=66, 19) | 17.5 units on a scale | Standard Deviation 32.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C15D1 (n=62, 16) | 16.7 units on a scale | Standard Deviation 27.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C16D1 (n=53, 12) | 30.6 units on a scale | Standard Deviation 36.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C17D1 (n=47, 11) | 33.3 units on a scale | Standard Deviation 36.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C18D1 (n=44, 11) | 15.2 units on a scale | Standard Deviation 31.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C19D1 (n=40, 9) | 25.9 units on a scale | Standard Deviation 32.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C20D1 (n=35, 8) | 25.0 units on a scale | Standard Deviation 34.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C21D1 (n=30, 8) | 29.2 units on a scale | Standard Deviation 33 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C22D1 (n=24, 7) | 28.6 units on a scale | Standard Deviation 35.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C23D1 (n=23, 4) | 33.3 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C24D1 (n=20, 3) | 33.3 units on a scale | Standard Deviation 57.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 50.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C26D1 (n=14, 3) | 44.4 units on a scale | Standard Deviation 50.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Financial Difficulties: C27D1 (n=14, 2) | 66.7 units on a scale | Standard Deviation 47.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Appetite loss: EOT (n=49, 90) | 28.1 units on a scale | Standard Deviation 30.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global Qol: EOT (n=49, 90) | 46.4 units on a scale | Standard Deviation 25.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Physical Functioning: EOT (n=49, 90) | 66.2 units on a scale | Standard Deviation 27.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Role Functioning: EOT (n=49, 90) | 54.1 units on a scale | Standard Deviation 34.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Emotional Functioning: EOT (n=49, 90) | 74.5 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Cognitive Functioning: EOT (n=49, 90) | 80.0 units on a scale | Standard Deviation 24 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Social Function: EOT (n=49, 90) | 59.4 units on a scale | Standard Deviation 33.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Fatigue: EOT (n=49, 90) | 46.9 units on a scale | Standard Deviation 26.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Nausea and Vomiting: EOT (n=49, 90) | 15.7 units on a scale | Standard Deviation 20.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Pain: EOT (n=49, 90) | 33.7 units on a scale | Standard Deviation 31.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: Baseline (n=165, 162) | 58.1 units on a scale | Standard Deviation 22.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C2D1 (n=154, 133) | 58.1 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C3D1 (n=154, 106) | 59.4 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C4D1 (n=135, 90) | 61.1 units on a scale | Standard Deviation 20.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C5D1 (n=123, 74) | 64.1 units on a scale | Standard Deviation 22.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C6D1 (n=120, 70) | 67.5 units on a scale | Standard Deviation 23.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C7D1 (n=114, 52) | 66.5 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C8D1 (n=110, 43) | 66.9 units on a scale | Standard Deviation 25.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C9D1 (n=101, 37) | 66.4 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C10D1 (n=94, 33) | 67.4 units on a scale | Standard Deviation 26.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C11D1 (n=83, 25) | 71.0 units on a scale | Standard Deviation 21.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C12D1 (n=76, 23) | 65.6 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C13D1 (n=74, 21) | 66.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C14D1 (n=66, 19) | 65.8 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C15D1 (n=62, 16) | 66.1 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C16D1 (n=53, 12) | 63.2 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C17D1 (n=47, 11) | 69.7 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C18D1 (n=44, 11) | 70.5 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C19D1 (n=40, 9) | 72.2 units on a scale | Standard Deviation 20 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C20D1 (n=35, 8) | 60.4 units on a scale | Standard Deviation 21.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C21D1 (n=30, 8) | 63.5 units on a scale | Standard Deviation 23.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C22D1 (n=24, 7) | 64.3 units on a scale | Standard Deviation 24.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C23D1 (n=23, 4) | 50.0 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C24D1 (n=20, 3) | 55.6 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C25D1 (n=18, 3) | 61.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C26D1 (n=14, 3) | 55.6 units on a scale | Standard Deviation 12.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C27D1 (n=14, 2) | 41.7 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C28D1 (n=11, 2) | 54.2 units on a scale | Standard Deviation 17.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C29D1 (n=8, 2) | 41.7 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Global QoL: C35D1 (n=4, 0) | NA units on a scale | — |
Secondary
European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: 1 'Not at All' to 4 'Very Much'. Scores averaged, transformed to 0-100 scale; higher symptom score = greater degree of symptoms.
Time frame: Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks)
Population: FAS included all participants who were randomized to study treatment. Here N (number of participants analyzed) signifies participants who were evaluable for this measure and n signifies participants who were evaluable for specified time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C30D1 (n=8, 1) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C10D1 (n=94, 33) | 4.3 units on a scale | Standard Deviation 12.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C31D1 (n=7, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C15D1 (n=62, 16) | 4.8 units on a scale | Standard Deviation 16.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C32D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C7D1 (n=115, 52) | 13.0 units on a scale | Standard Deviation 21 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C16D1 (n=53, 12) | 6.3 units on a scale | Standard Deviation 18.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C34D1 (n=5, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C22D1 (n=24, 7) | 2.8 units on a scale | Standard Deviation 9.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C35D1 (n=4, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C17D1 (n=46, 11) | 5.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C8D1 (n=111, 43) | 10.8 units on a scale | Standard Deviation 20.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C18D1 (n=45, 11) | 3.7 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: EOT (n=48, 90) | 11.1 units on a scale | Standard Deviation 21 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: EOT (n=49, 90) | 3.4 units on a scale | Standard Deviation 10.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: Baseline (n=163, 158) | 23.1 units on a scale | Standard Deviation 27.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C19D1 (n=40, 9) | 5.8 units on a scale | Standard Deviation 19.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C2D1 (n=153, 125) | 15.0 units on a scale | Standard Deviation 23.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C9D1 (n=101, 37) | 11.2 units on a scale | Standard Deviation 19.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C3D1 (n=152, 104) | 11.4 units on a scale | Standard Deviation 20.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C20D1 (n=35, 8) | 3.8 units on a scale | Standard Deviation 13.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C4D1 (n=134, 90) | 12.7 units on a scale | Standard Deviation 22.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C23D1 (n=23, 4) | 2.9 units on a scale | Standard Deviation 9.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C5D1 (n=123, 73) | 14.4 units on a scale | Standard Deviation 23 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C21D1 (n=30, 8) | 7.8 units on a scale | Standard Deviation 22.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C6D1 (n=118, 68) | 10.7 units on a scale | Standard Deviation 18.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C10D1 (n=94, 33) | 11.3 units on a scale | Standard Deviation 21.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C7D1 (n=115, 51) | 11.3 units on a scale | Standard Deviation 20.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C22D1 (n=24, 7) | 2.8 units on a scale | Standard Deviation 9.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C8D1 (n=111, 42) | 10.5 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C11D1 (n=84, 25) | 3.2 units on a scale | Standard Deviation 9.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C9D1 (n=100, 37) | 10.7 units on a scale | Standard Deviation 21.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C23D1 (n=23, 3) | 1.4 units on a scale | Standard Deviation 7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C10D1 (n=92, 33) | 9.8 units on a scale | Standard Deviation 18.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C11D1 (n=84, 25) | 11.1 units on a scale | Standard Deviation 21.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C11D1 (n=83, 25) | 12.4 units on a scale | Standard Deviation 21.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C24D1 (n=20, 3) | 6.7 units on a scale | Standard Deviation 23.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C12D1 (n=74, 23) | 12.2 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C24D1 (n=20, 3) | 5.0 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C13D1 (n=74, 21) | 10.8 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C25D1 (n=18, 3) | 9.3 units on a scale | Standard Deviation 27.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C14D1 (n=66, 19) | 11.6 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C12D1 (n=76, 23) | 11.4 units on a scale | Standard Deviation 22.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C15D1 (n=61, 16) | 9.8 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C26D1 (n=14, 3) | 7.1 units on a scale | Standard Deviation 26.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C16D1 (n=53, 12) | 10.7 units on a scale | Standard Deviation 19.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C5D1 (n=123, 74) | 6.0 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C17D1 (n=46, 11) | 13.8 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C27D1 (n=14, 2) | 16.7 units on a scale | Standard Deviation 36.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C18D1 (n=45, 11) | 10.4 units on a scale | Standard Deviation 19.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C13D1 (n=74, 21) | 10.4 units on a scale | Standard Deviation 19.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C19D1 (n=40, 9) | 14.2 units on a scale | Standard Deviation 22.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C28D1 (n=11, 2) | 6.1 units on a scale | Standard Deviation 20.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C20D1 (n=35, 8) | 13.3 units on a scale | Standard Deviation 20.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C25D1 (n=18, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C21D1 (n=30, 8) | 21.1 units on a scale | Standard Deviation 27 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C29D1 (n=8, 2) | 16.7 units on a scale | Standard Deviation 35.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C22D1 (n=24, 7) | 12.5 units on a scale | Standard Deviation 21.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C14D1 (n=66, 19) | 10.6 units on a scale | Standard Deviation 21.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C23D1 (n=23, 4) | 5.1 units on a scale | Standard Deviation 11.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C30D1 (n=8, 1) | 12.5 units on a scale | Standard Deviation 35.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C24D1 (n=20, 3) | 6.7 units on a scale | Standard Deviation 17.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C12D1 (n=76, 23) | 3.5 units on a scale | Standard Deviation 10.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C25D1 (n=18, 3) | 9.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C31D1 (n=7, 0) | 9.5 units on a scale | Standard Deviation 25.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C26D1 (n=14, 3) | 23.8 units on a scale | Standard Deviation 30.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C15D1 (n=62, 16) | 8.6 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C27D1 (n=14, 2) | 16.7 units on a scale | Standard Deviation 31.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C32D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C28D1 (n=11, 2) | 6.1 units on a scale | Standard Deviation 13.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C26D1 (n=14, 3) | 9.5 units on a scale | Standard Deviation 27.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C29D1 (n=8, 2) | 4.2 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C30D1 (n=8, 1) | 12.5 units on a scale | Standard Deviation 17.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C16D1 (n=52, 12) | 10.3 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C31D1 (n=7, 0) | 9.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C34D1 (n=5, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C32D1 (n=6, 0) | 5.6 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C2D1 (n=155, 132) | 8.2 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C35D1 (n=4, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C34D1 (n=5, 0) | 6.7 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C17D1 (n=47, 11) | 12.1 units on a scale | Standard Deviation 23.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C35D1 (n=4, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C27D1 (n=14, 2) | 2.4 units on a scale | Standard Deviation 8.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: EOT (n=49, 90) | 18.4 units on a scale | Standard Deviation 29.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C18D1 (n=45, 11) | 11.9 units on a scale | Standard Deviation 22.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: Baseline (n=164, 162) | 27.2 units on a scale | Standard Deviation 21.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: EOT (n=49, 90) | 6.8 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C2D1 (n=155, 132) | 17.6 units on a scale | Standard Deviation 18.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C13D1 (n=74, 21) | 4.1 units on a scale | Standard Deviation 11 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C3D1 (n=153, 106) | 17.9 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: Baseline (n=163, 160) | 18.8 units on a scale | Standard Deviation 22.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C4D1 (n=135, 91) | 16.2 units on a scale | Standard Deviation 17.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C19D1 (n=40, 9) | 9.2 units on a scale | Standard Deviation 20 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C5D1 (n=123, 74) | 16.9 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C2D1 (n=155, 132) | 9.5 units on a scale | Standard Deviation 17.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C6D1 (n=119, 70) | 15.2 units on a scale | Standard Deviation 15.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C28D1 (n=11, 2) | 6.1 units on a scale | Standard Deviation 13.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C7D1 (n=115, 52) | 15.6 units on a scale | Standard Deviation 16.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C3D1 (n=153, 106) | 7.0 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C8D1 (n=111, 43) | 14.7 units on a scale | Standard Deviation 16 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C20D1 (n=35, 8) | 12.4 units on a scale | Standard Deviation 25.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C9D1 (n=101, 37) | 13.9 units on a scale | Standard Deviation 15.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C4D1 (n=135, 91) | 7.4 units on a scale | Standard Deviation 13.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C10D1 (n=94, 33) | 15.4 units on a scale | Standard Deviation 17 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C6D1 (n=119, 70) | 7.0 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C11D1 (n=84, 25) | 15.1 units on a scale | Standard Deviation 17.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C5D1 (n=123, 74) | 6.8 units on a scale | Standard Deviation 14.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C12D1 (n=76, 23) | 13.7 units on a scale | Standard Deviation 15.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C21D1 (n=30, 8) | 11.1 units on a scale | Standard Deviation 18.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C13D1 (n=74, 21) | 12.8 units on a scale | Standard Deviation 14 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C6D1 (n=119, 70) | 6.2 units on a scale | Standard Deviation 13 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C14D1 (n=66, 19) | 14.8 units on a scale | Standard Deviation 16.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C29D1 (n=8, 2) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C15D1 (n=62, 16) | 13.2 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C7D1 (n=115, 52) | 7.5 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C16D1 (n=53, 12) | 12.6 units on a scale | Standard Deviation 11.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C22D1 (n=24, 7) | 8.3 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C17D1 (n=46, 11) | 12.3 units on a scale | Standard Deviation 11.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C8D1 (n=111, 43) | 5.1 units on a scale | Standard Deviation 14.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C18D1 (n=45, 11) | 14.1 units on a scale | Standard Deviation 13.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C14D1 (n=66, 19) | 3.0 units on a scale | Standard Deviation 11.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C19D1 (n=40, 9) | 14.4 units on a scale | Standard Deviation 13.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C9D1 (n=101, 37) | 5.9 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C20D1 (n=35, 8) | 13.7 units on a scale | Standard Deviation 12.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C23D1 (n=23, 4) | 8.7 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C21D1 (n=30, 8) | 12.6 units on a scale | Standard Deviation 13 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C10D1 (n=94, 33) | 6.7 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C22D1 (n=24, 7) | 10.6 units on a scale | Standard Deviation 11.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C30D1 (n=8, 1) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C23D1 (n=23, 4) | 13.8 units on a scale | Standard Deviation 14.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C11D1 (n=84, 25) | 6.3 units on a scale | Standard Deviation 13.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C24D1 (n=20, 3) | 14.4 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C24D1 (n=20, 3) | 3.3 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: EOT (n=49, 90) | 21.8 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C12D1 (n=76, 23) | 5.3 units on a scale | Standard Deviation 12.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: Baseline (n=164, 162) | 38.2 units on a scale | Standard Deviation 27.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C32D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C2D1 (n=155, 132) | 23.0 units on a scale | Standard Deviation 19.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C13D1 (n=74, 21) | 6.3 units on a scale | Standard Deviation 13.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C3D1 (n=153, 106) | 23.5 units on a scale | Standard Deviation 21.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C25D1 (n=18, 3) | 9.3 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C4D1 (n=135, 91) | 19.8 units on a scale | Standard Deviation 22.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C14D1 (n=66, 19) | 7.6 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C5D1 (n=123, 74) | 18.4 units on a scale | Standard Deviation 21 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C31D1 (n=7, 0) | 4.8 units on a scale | Standard Deviation 12.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C6D1 (n=119, 70) | 14.6 units on a scale | Standard Deviation 18.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C15D1 (n=62, 16) | 5.9 units on a scale | Standard Deviation 14.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C7D1 (n=115, 52) | 15.9 units on a scale | Standard Deviation 18.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C26D1 (n=14, 3) | 16.7 units on a scale | Standard Deviation 36.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C8D1 (n=111, 43) | 13.2 units on a scale | Standard Deviation 18.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C16D1 (n=53, 12) | 3.8 units on a scale | Standard Deviation 10.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C9D1 (n=101, 37) | 13.5 units on a scale | Standard Deviation 18.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C15D1 (n=62, 16) | 3.8 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C10D1 (n=94, 33) | 14.2 units on a scale | Standard Deviation 19.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C17D1 (n=46, 11) | 7.2 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C11D1 (n=83, 25) | 12.9 units on a scale | Standard Deviation 20.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C27D1 (n=14, 2) | 9.5 units on a scale | Standard Deviation 20.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C12D1 (n=76, 23) | 14.5 units on a scale | Standard Deviation 20.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C18D1 (n=45, 11) | 5.9 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C13D1 (n=74, 21) | 14.0 units on a scale | Standard Deviation 21.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C32D1 (n=6, 0) | 5.6 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C14D1 (n=66, 19) | 13.1 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C19D1 (n=40, 9) | 5.0 units on a scale | Standard Deviation 14.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C15D1 (n=62, 16) | 11.8 units on a scale | Standard Deviation 21 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C28D1 (n=11, 2) | 15.2 units on a scale | Standard Deviation 22.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C16D1 (n=53, 12) | 13.8 units on a scale | Standard Deviation 19 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C20D1 (n=35, 8) | 5.7 units on a scale | Standard Deviation 15.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C17D1 (n=47, 11) | 6.4 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C7D1 (n=115, 52) | 4.1 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C18D1 (n=45, 11) | 13.3 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C21D1 (n=30, 8) | 5.6 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C19D1 (n=40, 9) | 12.5 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C29D1 (n=8, 2) | 12.5 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C20D1 (n=35, 8) | 10.5 units on a scale | Standard Deviation 15.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C22D1 (n=24, 7) | 4.2 units on a scale | Standard Deviation 11.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C21D1 (n=30, 8) | 13.3 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C22D1 (n=24, 7) | 8.3 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C23D1 (n=23, 4) | 3.6 units on a scale | Standard Deviation 10 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C23D1 (n=23, 4) | 11.6 units on a scale | Standard Deviation 19.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C30D1 (n=8, 1) | 16.7 units on a scale | Standard Deviation 30.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C24D1 (n=20, 3) | 8.3 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C24D1 (n=20, 3) | 1.7 units on a scale | Standard Deviation 7.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C25D1 (n=18, 3) | 5.6 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C16D1 (n=53, 12) | 4.4 units on a scale | Standard Deviation 11.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C26D1 (n=14, 3) | 2.4 units on a scale | Standard Deviation 8.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C25D1 (n=18, 3) | 5.6 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C27D1 (n=14, 2) | 7.1 units on a scale | Standard Deviation 14.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C31D1 (n=7, 0) | 19.0 units on a scale | Standard Deviation 32.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C28D1 (n=11, 2) | 18.2 units on a scale | Standard Deviation 31.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C29D1 (n=8, 2) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C26D1 (n=14, 3) | 7.1 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C30D1 (n=8, 1) | 20.8 units on a scale | Standard Deviation 24.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C34D1 (n=5, 0) | 6.7 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C31D1 (n=7, 0) | 19.0 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C27D1 (n=14, 2) | 4.8 units on a scale | Standard Deviation 12.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C32D1 (n=6, 0) | 16.7 units on a scale | Standard Deviation 27.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C32D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C33D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 17.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C28D1 (n=11, 2) | 9.1 units on a scale | Standard Deviation 15.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C34D1 (n=5, 0) | 20.0 units on a scale | Standard Deviation 29.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C3D1 (n=153, 106) | 7.6 units on a scale | Standard Deviation 16.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C35D1 (n=4, 0) | 33.3 units on a scale | Standard Deviation 47.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C29D1 (n=8, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C36D1 (n=1, 0) | 33.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C33D1 (n=6, 0) | 11.1 units on a scale | Standard Deviation 27.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C37D1 (n=1, 0) | 33.3 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C30D1 (n=8, 1) | 4.2 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: EOT (n=49, 90) | 25.9 units on a scale | Standard Deviation 23.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C35D1 (n=4, 0) | 8.3 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: Baseline (n=164, 162) | 2.4 units on a scale | Standard Deviation 9.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C31D1 (n=7, 0) | 9.5 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C2D1 (n=155, 132) | 1.7 units on a scale | Standard Deviation 7.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C34D1 (n=5, 0) | 20.0 units on a scale | Standard Deviation 44.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C3D1 (n=153, 106) | 0.9 units on a scale | Standard Deviation 5.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C32D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C4D1 (n=135, 91) | 1.0 units on a scale | Standard Deviation 5.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C17D1 (n=47, 11) | 2.8 units on a scale | Standard Deviation 9.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C5D1 (n=123, 74) | 0.3 units on a scale | Standard Deviation 3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C6D1 (n=119, 70) | 0.6 units on a scale | Standard Deviation 4.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C35D1 (n=4, 0) | 25.0 units on a scale | Standard Deviation 50 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C7D1 (n=115, 52) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C34D1 (n=5, 0) | 6.7 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C8D1 (n=111, 43) | 0.9 units on a scale | Standard Deviation 7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C9D1 (n=101, 37) | 0.3 units on a scale | Standard Deviation 3.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C35D1 (n=4, 0) | 8.3 units on a scale | Standard Deviation 16.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C10D1 (n=94, 33) | 0.4 units on a scale | Standard Deviation 3.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C11D1 (n=83, 25) | 2.4 units on a scale | Standard Deviation 11.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C12D1 (n=76, 23) | 0.9 units on a scale | Standard Deviation 5.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C8D1 (n=111, 43) | 3.2 units on a scale | Standard Deviation 11.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C13D1 (n=74, 21) | 2.3 units on a scale | Standard Deviation 10.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C14D1 (n=66, 19) | 0.5 units on a scale | Standard Deviation 4.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C15D1 (n=62, 16) | 1.1 units on a scale | Standard Deviation 5.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: EOT (n=49, 90) | 17.0 units on a scale | Standard Deviation 24.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C16D1 (n=53, 12) | 0.6 units on a scale | Standard Deviation 4.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C17D1 (n=47, 11) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: Baseline (n=164, 161) | 16.3 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C18D1 (n=45, 11) | 1.5 units on a scale | Standard Deviation 6.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: EOT (n=49, 90) | 10.2 units on a scale | Standard Deviation 16.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C19D1 (n=40, 9) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C2D1 (n=155, 132) | 9.0 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C20D1 (n=35, 8) | 1.0 units on a scale | Standard Deviation 5.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C18D1 (n=45, 11) | 3.7 units on a scale | Standard Deviation 10.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C21D1 (n=30, 8) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C3D1 (n=153, 105) | 8.1 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C22D1 (n=24, 7) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: Baseline (n=163, 162) | 17.4 units on a scale | Standard Deviation 30.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C23D1 (n=23, 4) | 1.4 units on a scale | Standard Deviation 7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C4D1 (n=135, 91) | 6.9 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C24D1 (n=20, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: EOT (n=49, 90) | 4.8 units on a scale | Standard Deviation 13.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C25D1 (n=18, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C5D1 (n=123, 74) | 6.2 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C26D1 (n=14, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C2D1 (n=155, 132) | 9.5 units on a scale | Standard Deviation 21.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C27D1 (n=14, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C6D1 (n=119, 70) | 6.7 units on a scale | Standard Deviation 14.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C28D1 (n=11, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: Baseline (n=164, 162) | 7.1 units on a scale | Standard Deviation 16.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C29D1 (n=8, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C7D1 (n=115, 52) | 6.4 units on a scale | Standard Deviation 13.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C30D1 (n=8, 1) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C3D1 (n=153, 106) | 7.6 units on a scale | Standard Deviation 18.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C31D1 (n=7, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C8D1 (n=111, 43) | 6.9 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: Baseline (n=164, 162) | 14.0 units on a scale | Standard Deviation 22.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C9D1 (n=101, 37) | 5.6 units on a scale | Standard Deviation 12.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C34D1 (n=5, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C4D1 (n=135, 91) | 8.9 units on a scale | Standard Deviation 22 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C35D1 (n=4, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C10D1 (n=94, 33) | 7.4 units on a scale | Standard Deviation 17 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C19D1 (n=40, 9) | 4.2 units on a scale | Standard Deviation 11.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C11D1 (n=84, 25) | 6.0 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: EOT (n=49, 90) | 0.7 units on a scale | Standard Deviation 4.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C5D1 (n=123, 74) | 6.0 units on a scale | Standard Deviation 17.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: Baseline (n=164, 162) | 5.5 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C12D1 (n=76, 23) | 6.6 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C2D1 (n=155, 132) | 8.0 units on a scale | Standard Deviation 17.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C2D1 (n=155, 132) | 18.1 units on a scale | Standard Deviation 24.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C3D1 (n=153, 106) | 7.0 units on a scale | Standard Deviation 14.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C13D1 (n=74, 21) | 5.9 units on a scale | Standard Deviation 12.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C4D1 (n=135, 91) | 8.1 units on a scale | Standard Deviation 16.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C6D1 (n=118, 70) | 4.2 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C5D1 (n=123, 73) | 5.1 units on a scale | Standard Deviation 12.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C14D1 (n=66, 19) | 7.6 units on a scale | Standard Deviation 18.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C6D1 (n=119, 70) | 4.8 units on a scale | Standard Deviation 13.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C9D1 (n=101, 37) | 5.0 units on a scale | Standard Deviation 11.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C7D1 (n=115, 52) | 5.2 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C15D1 (n=62, 16) | 5.4 units on a scale | Standard Deviation 13.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C8D1 (n=111, 43) | 3.0 units on a scale | Standard Deviation 9.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C7D1 (n=115, 52) | 4.9 units on a scale | Standard Deviation 14.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C9D1 (n=101, 37) | 4.8 units on a scale | Standard Deviation 12.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C16D1 (n=53, 12) | 5.0 units on a scale | Standard Deviation 12 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C10D1 (n=94, 33) | 6.4 units on a scale | Standard Deviation 14.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C3D1 (n=153, 106) | 17.6 units on a scale | Standard Deviation 26.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C11D1 (n=84, 25) | 4.8 units on a scale | Standard Deviation 14.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C17D1 (n=47, 11) | 3.5 units on a scale | Standard Deviation 10.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C12D1 (n=76, 23) | 3.9 units on a scale | Standard Deviation 12.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C8D1 (n=111, 43) | 3.9 units on a scale | Standard Deviation 11.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C13D1 (n=74, 21) | 4.5 units on a scale | Standard Deviation 12.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C18D1 (n=45, 11) | 8.1 units on a scale | Standard Deviation 20.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C14D1 (n=66, 19) | 4.5 units on a scale | Standard Deviation 12.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C20D1 (n=35, 8) | 4.8 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C15D1 (n=62, 16) | 5.4 units on a scale | Standard Deviation 12.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C19D1 (n=40, 9) | 6.7 units on a scale | Standard Deviation 15.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C16D1 (n=53, 12) | 6.3 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C9D1 (n=101, 37) | 4.0 units on a scale | Standard Deviation 11.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C17D1 (n=47, 11) | 3.5 units on a scale | Standard Deviation 10.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C20D1 (n=35, 8) | 9.5 units on a scale | Standard Deviation 22.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C18D1 (n=45, 11) | 5.2 units on a scale | Standard Deviation 12.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C4D1 (n=134, 91) | 15.9 units on a scale | Standard Deviation 23 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C19D1 (n=40, 9) | 4.2 units on a scale | Standard Deviation 11.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C21D1 (n=30, 8) | 7.8 units on a scale | Standard Deviation 16.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C20D1 (n=35, 8) | 7.6 units on a scale | Standard Deviation 16.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C10D1 (n=94, 33) | 4.6 units on a scale | Standard Deviation 14.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C21D1 (n=30, 8) | 4.4 units on a scale | Standard Deviation 11.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C22D1 (n=24, 7) | 2.8 units on a scale | Standard Deviation 9.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C22D1 (n=24, 7) | 5.6 units on a scale | Standard Deviation 12.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C4D1 (n=135, 91) | 6.2 units on a scale | Standard Deviation 15.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C23D1 (n=23, 4) | 5.1 units on a scale | Standard Deviation 11.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C23D1 (n=23, 4) | 0.7 units on a scale | Standard Deviation 3.5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C24D1 (n=20, 3) | 6.7 units on a scale | Standard Deviation 17.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C11D1 (n=84, 25) | 4.0 units on a scale | Standard Deviation 15 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C25D1 (n=18, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C24D1 (n=20, 3) | 3.3 units on a scale | Standard Deviation 10.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C26D1 (n=14, 3) | 4.8 units on a scale | Standard Deviation 17.8 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C5D1 (n=123, 74) | 15.2 units on a scale | Standard Deviation 21 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C27D1 (n=14, 2) | 7.1 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C25D1 (n=18, 3) | 1.9 units on a scale | Standard Deviation 7.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C28D1 (n=11, 2) | 6.1 units on a scale | Standard Deviation 20.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C12D1 (n=76, 23) | 4.4 units on a scale | Standard Deviation 14.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C29D1 (n=8, 2) | 8.3 units on a scale | Standard Deviation 15.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C26D1 (n=14, 3) | 7.1 units on a scale | Standard Deviation 19.3 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C30D1 (n=8, 1) | 8.3 units on a scale | Standard Deviation 23.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C21D1 (n=30, 8) | 3.3 units on a scale | Standard Deviation 10.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C31D1 (n=7, 0) | 9.5 units on a scale | Standard Deviation 25.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C27D1 (n=14, 2) | 4.8 units on a scale | Standard Deviation 12.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C32D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C13D1 (n=74, 21) | 6.3 units on a scale | Standard Deviation 18 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C33D1 (n=6, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C28D1 (n=11, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C34D1 (n=5, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C6D1 (n=119, 70) | 13.7 units on a scale | Standard Deviation 21.9 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C35D1 (n=4, 0) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C29D1 (n=8, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C36D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C14D1 (n=65, 19) | 3.6 units on a scale | Standard Deviation 14.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C37D1 (n=1, 0) | 0.0 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C37D1 (n=1, 0) | 11.1 units on a scale | — |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C25D1 (n=18, 3) | 15.4 units on a scale | Standard Deviation 12.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C26D1 (n=14, 3) | 14.3 units on a scale | Standard Deviation 10.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C27D1 (n=14, 2) | 15.1 units on a scale | Standard Deviation 11.2 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C28D1 (n=11, 2) | 11.1 units on a scale | Standard Deviation 8.6 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C29D1 (n=8, 2) | 12.5 units on a scale | Standard Deviation 11 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C30D1 (n=8, 1) | 9.7 units on a scale | Standard Deviation 7.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C31D1 (n=7, 0) | 15.9 units on a scale | Standard Deviation 8.7 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C32D1 (n=6, 0) | 18.5 units on a scale | Standard Deviation 9.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C33D1 (n=6, 0) | 18.5 units on a scale | Standard Deviation 9.1 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C34D1 (n=5, 0) | 20.0 units on a scale | Standard Deviation 5 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C35D1 (n=4, 0) | 16.7 units on a scale | Standard Deviation 6.4 |
| Crizotinib | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C36D1 (n=1, 0) | 22.2 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C25D1 (n=18, 3) | 40.7 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C26D1 (n=14, 3) | 44.4 units on a scale | Standard Deviation 22.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C27D1 (n=14, 2) | 55.6 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C28D1 (n=11, 2) | 61.1 units on a scale | Standard Deviation 7.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C29D1 (n=8, 2) | 50.0 units on a scale | Standard Deviation 7.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C24D1 (n=20, 3) | 48.1 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C30D1 (n=8, 1) | 77.8 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: EOT (n=49, 90) | 8.1 units on a scale | Standard Deviation 18.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: Baseline (n=164, 162) | 8.6 units on a scale | Standard Deviation 20.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C2D1 (n=155, 132) | 9.8 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C3D1 (n=153, 106) | 9.7 units on a scale | Standard Deviation 20.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C4D1 (n=135, 91) | 8.1 units on a scale | Standard Deviation 19.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C5D1 (n=123, 74) | 7.7 units on a scale | Standard Deviation 17 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C6D1 (n=119, 70) | 10.0 units on a scale | Standard Deviation 16.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C7D1 (n=115, 52) | 5.1 units on a scale | Standard Deviation 13.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C8D1 (n=111, 43) | 6.2 units on a scale | Standard Deviation 15 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C9D1 (n=101, 37) | 7.2 units on a scale | Standard Deviation 16 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C10D1 (n=94, 33) | 6.1 units on a scale | Standard Deviation 13.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C11D1 (n=84, 25) | 4.0 units on a scale | Standard Deviation 11.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C12D1 (n=76, 23) | 7.2 units on a scale | Standard Deviation 17.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C13D1 (n=74, 21) | 6.3 units on a scale | Standard Deviation 13.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C14D1 (n=66, 19) | 7.0 units on a scale | Standard Deviation 14 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C15D1 (n=62, 16) | 4.2 units on a scale | Standard Deviation 16.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C16D1 (n=53, 12) | 2.8 units on a scale | Standard Deviation 9.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C17D1 (n=47, 11) | 6.1 units on a scale | Standard Deviation 13.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C18D1 (n=45, 11) | 3.0 units on a scale | Standard Deviation 10.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C19D1 (n=40, 9) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C20D1 (n=35, 8) | 8.3 units on a scale | Standard Deviation 15.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C21D1 (n=30, 8) | 8.3 units on a scale | Standard Deviation 15.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C22D1 (n=24, 7) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C23D1 (n=23, 4) | 8.3 units on a scale | Standard Deviation 16.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C24D1 (n=20, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C25D1 (n=18, 3) | 11.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C26D1 (n=14, 3) | 11.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C27D1 (n=14, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C28D1 (n=11, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C29D1 (n=8, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dysphagia: EOT (n=49, 90) | 8.5 units on a scale | Standard Deviation 19.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: Baseline (n=164, 162) | 17.7 units on a scale | Standard Deviation 27.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C2D1 (n=155, 132) | 21.5 units on a scale | Standard Deviation 29.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C3D1 (n=153, 106) | 18.2 units on a scale | Standard Deviation 29.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C4D1 (n=134, 91) | 21.6 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C5D1 (n=123, 74) | 21.2 units on a scale | Standard Deviation 28.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C6D1 (n=119, 70) | 18.1 units on a scale | Standard Deviation 27 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C7D1 (n=115, 52) | 21.8 units on a scale | Standard Deviation 28.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C8D1 (n=111, 43) | 24.0 units on a scale | Standard Deviation 32.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C9D1 (n=101, 37) | 29.7 units on a scale | Standard Deviation 34.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C10D1 (n=94, 33) | 27.3 units on a scale | Standard Deviation 29.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C11D1 (n=84, 25) | 24.0 units on a scale | Standard Deviation 31.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C12D1 (n=76, 23) | 33.3 units on a scale | Standard Deviation 36.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C13D1 (n=74, 21) | 33.3 units on a scale | Standard Deviation 35 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C14D1 (n=66, 19) | 29.8 units on a scale | Standard Deviation 35 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C15D1 (n=62, 16) | 25.0 units on a scale | Standard Deviation 31 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C16D1 (n=52, 12) | 25.0 units on a scale | Standard Deviation 20.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C17D1 (n=47, 11) | 27.3 units on a scale | Standard Deviation 29.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C18D1 (n=45, 11) | 30.3 units on a scale | Standard Deviation 31.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C19D1 (n=40, 9) | 22.2 units on a scale | Standard Deviation 16.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C20D1 (n=35, 8) | 33.3 units on a scale | Standard Deviation 30.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C21D1 (n=30, 8) | 29.2 units on a scale | Standard Deviation 21.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C22D1 (n=24, 7) | 28.6 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C23D1 (n=23, 4) | 41.7 units on a scale | Standard Deviation 31.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C24D1 (n=20, 3) | 44.4 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C26D1 (n=14, 3) | 22.2 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C27D1 (n=14, 2) | 66.7 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C28D1 (n=11, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C29D1 (n=8, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Peripheral Neuropathy: EOT (n=49, 90) | 21.9 units on a scale | Standard Deviation 29.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: Baseline (n=163, 162) | 16.9 units on a scale | Standard Deviation 29.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C2D1 (n=155, 132) | 36.6 units on a scale | Standard Deviation 39.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C3D1 (n=153, 106) | 30.5 units on a scale | Standard Deviation 36.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C4D1 (n=135, 91) | 24.9 units on a scale | Standard Deviation 32 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C5D1 (n=123, 74) | 23.9 units on a scale | Standard Deviation 31 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C6D1 (n=118, 70) | 23.3 units on a scale | Standard Deviation 32.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C7D1 (n=115, 52) | 19.9 units on a scale | Standard Deviation 30.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C8D1 (n=111, 43) | 18.6 units on a scale | Standard Deviation 28.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C9D1 (n=101, 37) | 16.2 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C10D1 (n=94, 33) | 14.1 units on a scale | Standard Deviation 22.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C11D1 (n=84, 25) | 16.0 units on a scale | Standard Deviation 21.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C12D1 (n=76, 23) | 20.3 units on a scale | Standard Deviation 26.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C13D1 (n=74, 21) | 12.7 units on a scale | Standard Deviation 19.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C14D1 (n=65, 19) | 15.8 units on a scale | Standard Deviation 23.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C15D1 (n=62, 16) | 8.3 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C16D1 (n=53, 12) | 13.9 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C17D1 (n=46, 11) | 18.2 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C18D1 (n=45, 11) | 18.2 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C19D1 (n=40, 9) | 18.5 units on a scale | Standard Deviation 24.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C20D1 (n=35, 8) | 25.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C21D1 (n=30, 8) | 16.7 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C22D1 (n=24, 7) | 14.3 units on a scale | Standard Deviation 17.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C23D1 (n=23, 3) | 22.2 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C24D1 (n=20, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C25D1 (n=18, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C26D1 (n=14, 3) | 44.4 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C27D1 (n=14, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C29D1 (n=8, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Alopecia: EOT (n=49, 90) | 33.3 units on a scale | Standard Deviation 37.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: Baseline (n=163, 160) | 24.0 units on a scale | Standard Deviation 27.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C2D1 (n=155, 132) | 23.7 units on a scale | Standard Deviation 25.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C3D1 (n=153, 106) | 23.3 units on a scale | Standard Deviation 26.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C4D1 (n=135, 91) | 19.8 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C5D1 (n=123, 74) | 17.1 units on a scale | Standard Deviation 21.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C6D1 (n=119, 70) | 16.2 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C7D1 (n=115, 52) | 16.7 units on a scale | Standard Deviation 22.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C8D1 (n=111, 43) | 14.0 units on a scale | Standard Deviation 20.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C9D1 (n=101, 37) | 17.1 units on a scale | Standard Deviation 23.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C10D1 (n=94, 33) | 18.2 units on a scale | Standard Deviation 31.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C11D1 (n=84, 25) | 20.0 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C12D1 (n=76, 23) | 23.2 units on a scale | Standard Deviation 30.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C13D1 (n=74, 21) | 23.8 units on a scale | Standard Deviation 30.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C14D1 (n=66, 19) | 22.8 units on a scale | Standard Deviation 22.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C15D1 (n=62, 16) | 18.7 units on a scale | Standard Deviation 24.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C16D1 (n=53, 12) | 16.7 units on a scale | Standard Deviation 17.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C17D1 (n=46, 11) | 21.2 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C18D1 (n=45, 11) | 24.2 units on a scale | Standard Deviation 33.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C19D1 (n=40, 9) | 18.5 units on a scale | Standard Deviation 24.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C20D1 (n=35, 8) | 29.2 units on a scale | Standard Deviation 21.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C21D1 (n=30, 8) | 25.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C22D1 (n=24, 7) | 26.2 units on a scale | Standard Deviation 30.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C23D1 (n=23, 4) | 41.7 units on a scale | Standard Deviation 31.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C24D1 (n=20, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C25D1 (n=18, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C26D1 (n=14, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C29D1 (n=8, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C30D1 (n=8, 1) | 66.7 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Chest: EOT (n=49, 90) | 28.5 units on a scale | Standard Deviation 29.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: Baseline (n=164, 161) | 19.5 units on a scale | Standard Deviation 28 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C2D1 (n=155, 132) | 19.9 units on a scale | Standard Deviation 27 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C3D1 (n=153, 105) | 17.5 units on a scale | Standard Deviation 24.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C4D1 (n=135, 91) | 14.3 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C5D1 (n=123, 74) | 13.1 units on a scale | Standard Deviation 21.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C6D1 (n=119, 70) | 17.1 units on a scale | Standard Deviation 25.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C7D1 (n=115, 52) | 17.3 units on a scale | Standard Deviation 23.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C8D1 (n=111, 43) | 20.2 units on a scale | Standard Deviation 28.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C9D1 (n=101, 37) | 23.4 units on a scale | Standard Deviation 28.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C10D1 (n=94, 33) | 25.3 units on a scale | Standard Deviation 32.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C11D1 (n=84, 25) | 24.0 units on a scale | Standard Deviation 26.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C12D1 (n=76, 23) | 29.0 units on a scale | Standard Deviation 35.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C13D1 (n=74, 21) | 25.4 units on a scale | Standard Deviation 34.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C14D1 (n=66, 19) | 29.8 units on a scale | Standard Deviation 31.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C15D1 (n=62, 16) | 25.0 units on a scale | Standard Deviation 25.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C16D1 (n=53, 12) | 16.7 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C17D1 (n=47, 11) | 21.2 units on a scale | Standard Deviation 22.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C18D1 (n=45, 11) | 30.3 units on a scale | Standard Deviation 34.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C19D1 (n=40, 9) | 18.5 units on a scale | Standard Deviation 24.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C20D1 (n=35, 8) | 25.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C21D1 (n=30, 8) | 29.2 units on a scale | Standard Deviation 27.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C22D1 (n=24, 7) | 21.4 units on a scale | Standard Deviation 24.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C23D1 (n=23, 4) | 33.3 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C24D1 (n=20, 3) | 44.4 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C25D1 (n=18, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C26D1 (n=14, 3) | 22.2 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C28D1 (n=11, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C29D1 (n=8, 2) | 66.7 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Arm or Shoulder: EOT (n=48, 90) | 21.9 units on a scale | Standard Deviation 28.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: Baseline (n=163, 158) | 31.4 units on a scale | Standard Deviation 30.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C2D1 (n=153, 125) | 25.9 units on a scale | Standard Deviation 28 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C3D1 (n=152, 104) | 21.2 units on a scale | Standard Deviation 27.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C4D1 (n=134, 90) | 21.5 units on a scale | Standard Deviation 24.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C5D1 (n=123, 73) | 20.5 units on a scale | Standard Deviation 27.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C6D1 (n=118, 68) | 18.1 units on a scale | Standard Deviation 26 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C7D1 (n=115, 51) | 16.3 units on a scale | Standard Deviation 26.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C8D1 (n=111, 42) | 22.2 units on a scale | Standard Deviation 30.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C9D1 (n=100, 37) | 24.3 units on a scale | Standard Deviation 31.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C10D1 (n=92, 33) | 28.3 units on a scale | Standard Deviation 35.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C11D1 (n=83, 25) | 24.0 units on a scale | Standard Deviation 29.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C12D1 (n=74, 23) | 24.6 units on a scale | Standard Deviation 30.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C13D1 (n=74, 21) | 31.7 units on a scale | Standard Deviation 34.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C14D1 (n=66, 19) | 24.6 units on a scale | Standard Deviation 29.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C15D1 (n=61, 16) | 25.0 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C16D1 (n=53, 12) | 38.9 units on a scale | Standard Deviation 34.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C17D1 (n=46, 11) | 24.2 units on a scale | Standard Deviation 21.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C18D1 (n=45, 11) | 33.3 units on a scale | Standard Deviation 39.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C19D1 (n=40, 9) | 25.9 units on a scale | Standard Deviation 14.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C20D1 (n=35, 8) | 29.2 units on a scale | Standard Deviation 21.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C21D1 (n=30, 8) | 29.2 units on a scale | Standard Deviation 37.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C22D1 (n=24, 7) | 40.5 units on a scale | Standard Deviation 30.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C23D1 (n=23, 4) | 41.7 units on a scale | Standard Deviation 31.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C24D1 (n=20, 3) | 11.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 38.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C26D1 (n=14, 3) | 33.3 units on a scale | Standard Deviation 33.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C28D1 (n=11, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C29D1 (n=8, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C28D1 (n=11, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Pain in Other Parts: EOT (n=49, 90) | 29.6 units on a scale | Standard Deviation 34.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: Baseline (n=164, 162) | 26.9 units on a scale | Standard Deviation 23.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C2D1 (n=155, 132) | 28.6 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C3D1 (n=153, 106) | 28.0 units on a scale | Standard Deviation 25.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C4D1 (n=135, 91) | 27.5 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C5D1 (n=123, 74) | 24.8 units on a scale | Standard Deviation 22.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C6D1 (n=119, 70) | 25.2 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C7D1 (n=115, 52) | 24.4 units on a scale | Standard Deviation 20.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C8D1 (n=111, 43) | 22.0 units on a scale | Standard Deviation 22.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C9D1 (n=101, 37) | 19.5 units on a scale | Standard Deviation 19 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C10D1 (n=94, 33) | 21.5 units on a scale | Standard Deviation 21 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C11D1 (n=84, 25) | 20.4 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C12D1 (n=76, 23) | 22.7 units on a scale | Standard Deviation 22.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C13D1 (n=74, 21) | 26.5 units on a scale | Standard Deviation 25.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C14D1 (n=66, 19) | 26.3 units on a scale | Standard Deviation 26.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C15D1 (n=62, 16) | 22.9 units on a scale | Standard Deviation 18.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C16D1 (n=53, 12) | 22.2 units on a scale | Standard Deviation 18.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C17D1 (n=46, 11) | 30.3 units on a scale | Standard Deviation 23.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C18D1 (n=45, 11) | 26.3 units on a scale | Standard Deviation 20.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C19D1 (n=40, 9) | 23.5 units on a scale | Standard Deviation 15.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C20D1 (n=35, 8) | 34.7 units on a scale | Standard Deviation 24.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C21D1 (n=30, 8) | 25.0 units on a scale | Standard Deviation 14.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C22D1 (n=24, 7) | 27.0 units on a scale | Standard Deviation 21.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C23D1 (n=23, 4) | 52.8 units on a scale | Standard Deviation 19 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Dyspnea: EOT (n=49, 90) | 35.6 units on a scale | Standard Deviation 26.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: Baseline (n=164, 162) | 42.2 units on a scale | Standard Deviation 31.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C2D1 (n=155, 132) | 34.8 units on a scale | Standard Deviation 26.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C3D1 (n=153, 106) | 32.4 units on a scale | Standard Deviation 27.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C4D1 (n=135, 91) | 27.1 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C5D1 (n=123, 74) | 25.7 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C6D1 (n=119, 70) | 30.0 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C7D1 (n=115, 52) | 26.3 units on a scale | Standard Deviation 23.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C8D1 (n=111, 43) | 22.5 units on a scale | Standard Deviation 23.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C9D1 (n=101, 37) | 25.2 units on a scale | Standard Deviation 28.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C10D1 (n=94, 33) | 20.2 units on a scale | Standard Deviation 26.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C11D1 (n=83, 25) | 18.7 units on a scale | Standard Deviation 25.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C12D1 (n=76, 23) | 23.2 units on a scale | Standard Deviation 25.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C13D1 (n=74, 21) | 27.0 units on a scale | Standard Deviation 27.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C14D1 (n=66, 19) | 24.6 units on a scale | Standard Deviation 31.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C15D1 (n=62, 16) | 20.8 units on a scale | Standard Deviation 20.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C16D1 (n=53, 12) | 22.2 units on a scale | Standard Deviation 21.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C17D1 (n=47, 11) | 27.3 units on a scale | Standard Deviation 25 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C18D1 (n=45, 11) | 18.2 units on a scale | Standard Deviation 17.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C19D1 (n=40, 9) | 14.8 units on a scale | Standard Deviation 17.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C20D1 (n=35, 8) | 29.2 units on a scale | Standard Deviation 21.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C21D1 (n=30, 8) | 33.3 units on a scale | Standard Deviation 25.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C22D1 (n=24, 7) | 28.6 units on a scale | Standard Deviation 23 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C23D1 (n=23, 4) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C24D1 (n=20, 3) | 44.4 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C25D1 (n=18, 3) | 44.4 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C26D1 (n=14, 3) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C27D1 (n=14, 2) | 50.0 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C29D1 (n=8, 2) | 33.3 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C30D1 (n=8, 1) | 33.3 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Coughing: EOT (n=49, 90) | 37.4 units on a scale | Standard Deviation 29.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: Baseline (n=164, 162) | 3.7 units on a scale | Standard Deviation 12.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C2D1 (n=155, 132) | 3.5 units on a scale | Standard Deviation 12.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C3D1 (n=153, 106) | 2.2 units on a scale | Standard Deviation 8.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C4D1 (n=135, 91) | 1.5 units on a scale | Standard Deviation 6.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C5D1 (n=123, 74) | 0.9 units on a scale | Standard Deviation 5.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C6D1 (n=119, 70) | 3.8 units on a scale | Standard Deviation 14.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C7D1 (n=115, 52) | 1.3 units on a scale | Standard Deviation 9.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C8D1 (n=111, 43) | 2.3 units on a scale | Standard Deviation 11.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C9D1 (n=101, 37) | 2.7 units on a scale | Standard Deviation 12.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C10D1 (n=94, 33) | 3.0 units on a scale | Standard Deviation 17.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C11D1 (n=83, 25) | 4.0 units on a scale | Standard Deviation 14.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C12D1 (n=76, 23) | 5.8 units on a scale | Standard Deviation 21.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C13D1 (n=74, 21) | 4.8 units on a scale | Standard Deviation 15.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C14D1 (n=66, 19) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C15D1 (n=62, 16) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C16D1 (n=53, 12) | 5.6 units on a scale | Standard Deviation 13 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C17D1 (n=47, 11) | 9.1 units on a scale | Standard Deviation 21.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C18D1 (n=45, 11) | 3.0 units on a scale | Standard Deviation 10.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C19D1 (n=40, 9) | 3.7 units on a scale | Standard Deviation 11.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C20D1 (n=35, 8) | 8.3 units on a scale | Standard Deviation 15.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C21D1 (n=30, 8) | 4.2 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C22D1 (n=24, 7) | 9.5 units on a scale | Standard Deviation 16.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C23D1 (n=23, 4) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C24D1 (n=20, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C25D1 (n=18, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C26D1 (n=14, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C27D1 (n=14, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C28D1 (n=11, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C29D1 (n=8, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C30D1 (n=8, 1) | 0.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: C37D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Hemoptysis: EOT (n=49, 90) | 4.8 units on a scale | Standard Deviation 13.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: Baseline (n=164, 162) | 6.4 units on a scale | Standard Deviation 18.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C2D1 (n=155, 132) | 9.1 units on a scale | Standard Deviation 18.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C3D1 (n=153, 106) | 9.4 units on a scale | Standard Deviation 21 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C4D1 (n=135, 91) | 10.3 units on a scale | Standard Deviation 21.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C5D1 (n=123, 73) | 9.6 units on a scale | Standard Deviation 20.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C6D1 (n=119, 70) | 10.5 units on a scale | Standard Deviation 19.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C7D1 (n=115, 52) | 7.7 units on a scale | Standard Deviation 15.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C8D1 (n=111, 43) | 10.9 units on a scale | Standard Deviation 18.9 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C9D1 (n=101, 37) | 10.8 units on a scale | Standard Deviation 22.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C10D1 (n=94, 33) | 12.1 units on a scale | Standard Deviation 23.3 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C11D1 (n=84, 25) | 9.3 units on a scale | Standard Deviation 18.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C12D1 (n=76, 23) | 8.7 units on a scale | Standard Deviation 18 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C13D1 (n=74, 21) | 9.5 units on a scale | Standard Deviation 15.4 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C14D1 (n=66, 19) | 7.0 units on a scale | Standard Deviation 14 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C15D1 (n=62, 16) | 14.6 units on a scale | Standard Deviation 29.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C16D1 (n=53, 12) | 8.3 units on a scale | Standard Deviation 15.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C17D1 (n=47, 11) | 6.1 units on a scale | Standard Deviation 13.5 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C18D1 (n=45, 11) | 12.1 units on a scale | Standard Deviation 16.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C19D1 (n=40, 9) | 7.4 units on a scale | Standard Deviation 14.7 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C20D1 (n=35, 8) | 12.5 units on a scale | Standard Deviation 24.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C21D1 (n=30, 8) | 4.2 units on a scale | Standard Deviation 11.8 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C22D1 (n=24, 7) | 7.1 units on a scale | Standard Deviation 13.1 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C23D1 (n=23, 4) | 16.7 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C24D1 (n=20, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C25D1 (n=18, 3) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C26D1 (n=14, 3) | 11.1 units on a scale | Standard Deviation 19.2 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C27D1 (n=14, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C28D1 (n=11, 2) | 0.0 units on a scale | Standard Deviation 0 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C29D1 (n=8, 2) | 16.7 units on a scale | Standard Deviation 23.6 |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C30D1 (n=8, 1) | 0.0 units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13) | Sore Mouth: C36D1 (n=1, 0) | NA units on a scale | — |
Secondary
European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
Time frame: Baseline, Day 1 of each cycle until disease progression, end of treatment (up to 112 weeks)
Population: FAS included all participants who were randomized to study treatment. Here N (number of participants analyzed) signifies participants who were evaluable for this measure and n signifies participants who were evaluable for specified time points for each arm group, respectively.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C20D1 (n=35, 8) | 72.66 units on a scale | Standard Deviation 19.81 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C11D1 (n=84, 25) | 76.32 units on a scale | Standard Deviation 17 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C21D1 (n=30, 8) | 74.13 units on a scale | Standard Deviation 16.19 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C4D1 (n=135, 90) | 73.78 units on a scale | Standard Deviation 18.25 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C22D1 (n=24, 7) | 77.54 units on a scale | Standard Deviation 17.54 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C12D1 (n=77, 23) | 76.95 units on a scale | Standard Deviation 17.63 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C23D1 (n=23, 4) | 75.48 units on a scale | Standard Deviation 17.75 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C7D1 (n=115, 52) | 77.02 units on a scale | Standard Deviation 17.34 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C24D1 (n=20, 3) | 71.40 units on a scale | Standard Deviation 23.15 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C13D1 (n=73, 21) | 76.38 units on a scale | Standard Deviation 17.5 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C25D1 (n=18, 3) | 75.61 units on a scale | Standard Deviation 15.97 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C3D1 (n=153, 105) | 73.13 units on a scale | Standard Deviation 18.97 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C26D1 (n=14, 3) | 72.14 units on a scale | Standard Deviation 20.71 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C14D1 (n=66, 19) | 78.77 units on a scale | Standard Deviation 15.54 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C27D1 (n=14, 2) | 66.57 units on a scale | Standard Deviation 16.96 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C8D1 (n=110, 43) | 74.72 units on a scale | Standard Deviation 18.09 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C28D1 (n=11, 2) | 72.36 units on a scale | Standard Deviation 12.72 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C15D1 (n=62, 16) | 77.71 units on a scale | Standard Deviation 16.78 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C29D1 (n=8, 2) | 71.38 units on a scale | Standard Deviation 12.28 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C5D1 (n=122, 74) | 75.27 units on a scale | Standard Deviation 17.99 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C30D1 (n=8, 1) | 69.50 units on a scale | Standard Deviation 17 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C16D1 (n=53, 12) | 75.32 units on a scale | Standard Deviation 16.21 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C31D1 (n=7, 0) | 68.57 units on a scale | Standard Deviation 16.76 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C9D1 (n=101, 37) | 74.45 units on a scale | Standard Deviation 18.32 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C32D1 (n=6, 0) | 65.83 units on a scale | Standard Deviation 19.41 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C17D1 (n=47, 11) | 75.09 units on a scale | Standard Deviation 17.68 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C33D1 (n=6, 0) | 67.50 units on a scale | Standard Deviation 20.34 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C2D1 (n=153, 131) | 69.19 units on a scale | Standard Deviation 19.42 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C34D1 (n=5, 0) | 68.00 units on a scale | Standard Deviation 20.8 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C18D1 (n=45, 11) | 75.87 units on a scale | Standard Deviation 16.63 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C35D1 (n=4, 0) | 72.25 units on a scale | Standard Deviation 14.84 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C10D1 (n=94, 33) | 75.49 units on a scale | Standard Deviation 18.18 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C36D1 (n=1, 0) | 90.00 units on a scale | — |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C19D1 (n=40, 9) | 76.85 units on a scale | Standard Deviation 16.39 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C37D1 (n=1, 0) | 85.00 units on a scale | — |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C6D1 (n=120, 70) | 75.79 units on a scale | Standard Deviation 18.67 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | EOT (n=49, 90) | 68.33 units on a scale | Standard Deviation 21.25 |
| Crizotinib | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | Baseline (n=164, 161) | 64.09 units on a scale | Standard Deviation 21.04 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | EOT (n=49, 90) | 58.34 units on a scale | Standard Deviation 23.71 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | Baseline (n=164, 161) | 66.76 units on a scale | Standard Deviation 20.74 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C2D1 (n=153, 131) | 66.33 units on a scale | Standard Deviation 20.3 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C3D1 (n=153, 105) | 65.84 units on a scale | Standard Deviation 20.8 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C4D1 (n=135, 90) | 69.13 units on a scale | Standard Deviation 18.14 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C5D1 (n=122, 74) | 68.12 units on a scale | Standard Deviation 23.19 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C6D1 (n=120, 70) | 69.71 units on a scale | Standard Deviation 22.46 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C7D1 (n=115, 52) | 70.63 units on a scale | Standard Deviation 24.31 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C8D1 (n=110, 43) | 72.30 units on a scale | Standard Deviation 23.54 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C9D1 (n=101, 37) | 72.27 units on a scale | Standard Deviation 25.85 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C10D1 (n=94, 33) | 74.27 units on a scale | Standard Deviation 24.88 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C11D1 (n=84, 25) | 77.24 units on a scale | Standard Deviation 20.31 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C12D1 (n=77, 23) | 74.83 units on a scale | Standard Deviation 22.6 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C13D1 (n=73, 21) | 73.00 units on a scale | Standard Deviation 23.54 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C14D1 (n=66, 19) | 74.11 units on a scale | Standard Deviation 22.56 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C15D1 (n=62, 16) | 77.44 units on a scale | Standard Deviation 19.52 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C16D1 (n=53, 12) | 79.00 units on a scale | Standard Deviation 13.28 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C17D1 (n=47, 11) | 81.73 units on a scale | Standard Deviation 15.98 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C18D1 (n=45, 11) | 78.91 units on a scale | Standard Deviation 16.25 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C19D1 (n=40, 9) | 78.00 units on a scale | Standard Deviation 14.04 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C20D1 (n=35, 8) | 76.75 units on a scale | Standard Deviation 17.65 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C21D1 (n=30, 8) | 73.63 units on a scale | Standard Deviation 19.41 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C22D1 (n=24, 7) | 72.21 units on a scale | Standard Deviation 19.79 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C23D1 (n=23, 4) | 54.00 units on a scale | Standard Deviation 16.35 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C24D1 (n=20, 3) | 62.00 units on a scale | Standard Deviation 20.3 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C25D1 (n=18, 3) | 63.67 units on a scale | Standard Deviation 22.59 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C26D1 (n=14, 3) | 63.00 units on a scale | Standard Deviation 17.52 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C27D1 (n=14, 2) | 50.00 units on a scale | Standard Deviation 14.14 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C28D1 (n=11, 2) | 55.00 units on a scale | Standard Deviation 21.21 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C29D1 (n=8, 2) | 45.00 units on a scale | Standard Deviation 14.14 |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C30D1 (n=8, 1) | 40.00 units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C31D1 (n=7, 0) | NA units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C32D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C33D1 (n=6, 0) | NA units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C34D1 (n=5, 0) | NA units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C35D1 (n=4, 0) | NA units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C36D1 (n=1, 0) | NA units on a scale | — |
| Chemotherapy | European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS) | C37D1 (n=1, 0) | NA units on a scale | — |
Secondary
Number of Participants With Categorical Maximum QTcF for Crizotinib
QT interval corrected using Fridericia's formula (QTcF): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\<) 450 milliseconds (msec), 450 msec to \<480 msec, 480 msec to \<500 msec, and more than or equal to (\>=) 500 msec. A participant is reported only once under the maximum QTcF interval observed at any of the time-points. Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.
Time frame: Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 1, 2
Population: ECG-evaluable population included all randomized participants who received at least 1 dose of study treatment, and had a baseline and at least 1 post-baseline ECG measurement.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crizotinib | Number of Participants With Categorical Maximum QTcF for Crizotinib | >=500 msec | 8 participants |
| Crizotinib | Number of Participants With Categorical Maximum QTcF for Crizotinib | 480 msec to <500 msec | 1 participants |
| Crizotinib | Number of Participants With Categorical Maximum QTcF for Crizotinib | <450 msec | 137 participants |
| Crizotinib | Number of Participants With Categorical Maximum QTcF for Crizotinib | 450 msec to <480 msec | 9 participants |
Secondary
Overall Survival (OS)
OS: Time in months from randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4.
Time frame: Randomization until death (up to 4.5 years)
Population: FAS included all participants who were randomized to study treatment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib | Overall Survival (OS) | 21.7 months |
| Chemotherapy | Overall Survival (OS) | 21.9 months |
Comparison: P-value was obtained from 1-sided log-rank test stratified by ECOG PS score, brain metastases, and prior EGFR TKI treatment. The hazard ratio and corresponding 95% CI from the stratified Cox proportional hazards model were also presented.p-value: 0.114595% CI: [0.661, 1.104]Log Rank
Secondary
Overall Survival Probability at Months 6 and 12
Overall survival probability at Month 6 and 12 was defined as the probability of survival at 6 and 12 months respectively, after the randomization of study treatment. The survival probability was estimated using the Kaplan-Meier method.
Time frame: Month 6, 12
Population: FAS included all participants who were randomized to study treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Crizotinib | Overall Survival Probability at Months 6 and 12 | Month 6 | 86.6 percent chance of survival |
| Crizotinib | Overall Survival Probability at Months 6 and 12 | Month 12 | 70.4 percent chance of survival |
| Chemotherapy | Overall Survival Probability at Months 6 and 12 | Month 6 | 83.8 percent chance of survival |
| Chemotherapy | Overall Survival Probability at Months 6 and 12 | Month 12 | 66.7 percent chance of survival |
Secondary
Percentage of Participants With Disease Control at Week 12
Disease control: participants with CR, PR, or SD according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: Week 12
Population: FAS included all participants who were randomized to study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crizotinib | Percentage of Participants With Disease Control at Week 12 | 64.2 percentage of participants |
| Chemotherapy | Percentage of Participants With Disease Control at Week 12 | 38.5 percentage of participants |
Comparison: P-value was obtained from CMH test stratified by ECOG PS, brain metastases, and prior EGFR TKI treatment. The risk ratio and corresponding 95% CI from the stratified CMH test were also reported.p-value: <0.000195% CI: [1.368, 2.103]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Disease Control at Week 6
Disease control: participants with CR, PR, or stable disease (SD) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions. Disease control is based on independent radiology review.
Time frame: Week 6
Population: FAS included all participants who were randomized to study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crizotinib | Percentage of Participants With Disease Control at Week 6 | 81.5 percentage of participants |
| Chemotherapy | Percentage of Participants With Disease Control at Week 6 | 55.2 percentage of participants |
Comparison: P-value was obtained from CMH test stratified by ECOG PS, brain metastases, and prior EGFR TKI treatment. The risk ratio and corresponding 95% CI from the stratified CMH test were also reported.p-value: <0.000195% CI: [1.297, 1.741]Cochran-Mantel-Haenszel
Secondary
Percentage of Participants With Objective Response (OR)
Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 millimeter \[mm\] short axis). PR: at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. Objective response is based on independent radiology review.
Time frame: Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)
Population: FAS included all participants who were randomized to study treatment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crizotinib | Percentage of Participants With Objective Response (OR) | 65.3 percentage of participants |
| Chemotherapy | Percentage of Participants With Objective Response (OR) | 19.5 percentage of participants |
Comparison: P-value was obtained from Cochran-Mantel-Haenszel (CMH) test stratified by ECOG PS, brain metastases, and prior EGFR TKI treatment. The risk ratio and corresponding 95% CI from the stratified CMH test were also reported.p-value: <0.000195% CI: [2.463, 4.676]Cochran-Mantel-Haenszel
Secondary
Plasma Concentration of Crizotinib
Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.
Time frame: Pre-dose on Cycle 1 Day 1, Cycle 1 Day 15, and Day 1 of Cycles 2, 3, 5
Population: Pharmacokinetic (PK) analysis population included all randomized participants who received at least 1 dose of study treatment and had 1 of the PK parameters of interest. Here N (number of participants analyzed) signifies participants evaluable for this measure. n=participants evaluable at specific time points.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|---|
| Crizotinib | Plasma Concentration of Crizotinib | Cycle 3 Day 1 (n=61) | 306 nanogram per milliliter (ng/mL) | Standard Deviation 135 |
| Crizotinib | Plasma Concentration of Crizotinib | Cycle 5 Day 1 (n=47) | 291 nanogram per milliliter (ng/mL) | Standard Deviation 156 |
| Crizotinib | Plasma Concentration of Crizotinib | Cycle 1 Day 1 (n=15) | NA nanogram per milliliter (ng/mL) | — |
| Crizotinib | Plasma Concentration of Crizotinib | Cycle 1 Day 15 (n=92) | 298 nanogram per milliliter (ng/mL) | Standard Deviation 148 |
| Crizotinib | Plasma Concentration of Crizotinib | Cycle 2 Day 1 (n=62) | 293 nanogram per milliliter (ng/mL) | Standard Deviation 154 |
Secondary
Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins
Descriptive statistics (absolute value and change from baseline as measured by ratio to baseline) for each best overall response category (CR, PR, SD, PD or combined) have been used to summarize the data from optional soluble c-Met ectodomain assays for crizotinib treated patients.
Time frame: Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 2, end of treatment (up to 112 weeks)
Population: The soluble biomarker-evaluable population includes patients from the SA population that received PF-02341066, who have an optional blood sample prior to dosing on Cycle 1 Day 1 and have at least 1 on-treatment soluble biomarker evaluation (Cycle 2 Day 1 and/or end of treatment).
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Crizotinib | Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins | Baseline (N = 81) | 1428.3 nanogram per milliliter (ng/mL) | Standard Deviation 363.9 |
| Crizotinib | Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins | Cycle 2 Day 1 6-hour post dose (N = 69) | 1683.0 nanogram per milliliter (ng/mL) | Standard Deviation 325.6 |
| Crizotinib | Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins | End of treatment (N = 40) | 1751.8 nanogram per milliliter (ng/mL) | Standard Deviation 327.9 |
Secondary
Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough
TTD in pain (pain in chest from European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer \[EORTC QLQ-LC13\]), dyspnea (from EORTC QLQ-LC13), or cough (from EORTC QLQ-LC13) symptoms was defined as the time from randomization to the earliest time the participant's score showed a 10 point or higher increase from baseline in any of the three symptoms from the instrument. The transformed score of pain, dyspnea, and cough symptom scales of EORTC QLQ-LC13 range from 0 to 100, greater scores = higher symptom severity.
Time frame: Baseline up to end of treatment (up to 112 weeks)
Population: Patient Reported Outcome (PRO) evaluable population included all randomized participants who received at least 1 dose of study treatment, and had a baseline and at least 1 post-baseline PRO assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib | Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough | 4.5 months |
| Chemotherapy | Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough | 1.4 months |
Comparison: The p-value was obtained from 2-sided unstratified log-rank test. The hazard ratio and corresponding 95% CI from the Cox Proportional Hazards model were also presented.p-value: <0.000195% CI: [0.373, 0.661]Log Rank
Secondary
Time to Tumor Response (TTR)
Time from date of randomization to first documentation of objective tumor response. TTR was calculated for the subgroup of participants with objective tumor response. Objective tumor response was defined as CR or PR according to RECIST v1.1. CR: disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\<10 mm short axis). PR: at least 30 % decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits.
Time frame: Randomization until PD or initiation of antitumor therapy in the absence of PD or death, assessed every 6 weeks (up to 112 weeks)
Population: FAS included all participants who were randomized to study treatment. Here 'N' (number of participant analyzed) signifies participants with objective tumor response.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib | Time to Tumor Response (TTR) | 6.3 weeks |
| Chemotherapy | Time to Tumor Response (TTR) | 12.6 weeks |